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are required for HA stalk specific antibodies and sustained protective HAI titers. T-bet+ HA-specific B cells 
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specific B cells are initially found in the spleen, lungs, and draining mediastinal lymph nodes; at later 
timepoints T-bethigh HA-specific memory B cells are restricted to the spleen, despite the continued 
presence of T-bet- HA-specific B cells at other anatomical locations. Parabiotic studies show that HA-
specific T-bethigh B cells are splenic residents, whereas T-betlow and T-bet- B cells recirculate. T-bethigh B 
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are a unique splenic resident population with stem cell like properties that sustains plasma cell numbers 








Michael P. Cancro 
Keywords 
B cell memory, Humoral immunity, Influenza, Plasma cells, T-bet+ B cells, Tissue-resident 
Subject Categories 
Allergy and Immunology | Immunology and Infectious Disease | Medical Immunology 
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/4047 
	
	
T-BET EXPRESSING B CELLS WITH DISTINCT RESIDENCY AND FUNCTIONAL 





Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2020 
 
Supervisor of Dissertation       
      
Michael P. Cancro       
Professor of Pathology and Laboratory Medicine       
 
Graduate Group Chairperson 
_________________ 
David M. Allman 
Professor of Pathology and Laboratory Medicine 
 
Dissertation Committee  
Eline T. Luning Prak, Professor of Pathology and Laboratory Medicine 
David M. Allman, Professor of Pathology and Laboratory Medicine 
Michael L. Atchison, Professor of Biomedical Sciences 




Dedication page  
 
I dedicate this dissertation to my family, without whom none of this would have 
been possible. To my mother, Sharon Rosenthal, for her unwavering love and 
support my entire life. To my father, Stanton Jay Rosenthal, for always 
encouraging my curiosity-you were my first and favorite teacher. I will always 
appreciate our dinnertime conversations of interesting medical cases even if they 
disgusted the rest of the family. To my sister, Anne Rosenthal, for helping me 
maintain my sanity and always encouraging me and believing in me, even when I 
doubted myself. To Adam Schroeder, you are like the brother I never had. 
 
To the memory of my grandparents, Lillian and Avrom Lustgarten who were like 
a second set of parents to me. Without your love and support I would not be the 
person I am today. I will always miss our weekly Sunday dinners and your 















I would like to thank Michael Cancro for agreeing to be my mentor and for his 
scientific support and advice. I would also like to acknowledge all the members of 
the Cancro lab for many helpful discussions and experimental aid and advice. I 
would especially like to thank John Johnson for his support and aid, both 
scientific and otherwise—I have greatly enjoyed all of our conversations. I would 
also like to thank Caleb Ng for his support and encouragement. You always 
believed in me and encouraged me even when I doubted myself. I would like to 
acknowledge my committee, Eline Luning Prak, David Allman, Michael Atchison, 
and Christopher Hunter for many helpful suggestions and discussions. I 
appreciate the support provided by the Immunology Graduate Group and the 
VMD/PhD program. I have greatly benefitted from being part of such an 
academic and supportive environment. Without all of you, much of this would not 















T-BET EXPRESSING B CELLS WITH DISTINCT RESIDENCY AND 
FUNCTIONAL CHARACTERISTICS GIVE RISE TO PLASMA CELLS  
Rebecca L. Rosenthal 
Michael P. Cancro 
An increasing body of work shows that T-bet+ B cells play important roles 
in immune responses to infections a well as in autoimmune diseases. These 
studies investigate the kinetics, tissue distribution, and functions of T-bet+ B cells 
in a murine influenza infection model. Both T-bet+ and T-bet- HA-specific B cells 
emerge early after infection, acquire the memory markers CD73, PD-L2 and 
CD80, and persist indefinitely with limited interconversion between T-bet+ and T-
bet- B cell pools. Moreover, T-bet+ B cells are required for HA stalk specific 
antibodies and sustained protective HAI titers. T-bet+ HA-specific B cells can be 
further divided into T-bethigh and T-betlow B cell pools. While T-bethigh, T-betlow, and 
T-bet- HA-specific B cells are initially found in the spleen, lungs, and draining 
mediastinal lymph nodes; at later timepoints T-bethigh HA-specific memory B cells 
are restricted to the spleen, despite the continued presence of T-bet- HA-specific 
B cells at other anatomical locations. Parabiotic studies show that HA-specific T-
bethigh B cells are splenic residents, whereas T-betlow and T-bet- B cells 
recirculate. T-bethigh B cells give rise to T-betlow B cells but T-betlow B cells do not 
become T-bethigh. However, T-betlow B cells persist for a minimum of three weeks 
in the absence of T-bethigh B cells, indicating that they are likely distinct 




betlow and T-bethigh B cells downregulate T-bet and give rise to plasma cells. Both 
B220+ and B220- plasma cells arise from T-bet+ B cells in the spleen and bone 
marrow. Together, these data suggest that T-bethigh memory B cells are a unique 
splenic resident population with stem cell like properties that sustains plasma cell 
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CHAPTER 1: Introduction  
1.1 Overview of Innate and Adaptive Immunity 
The immune system provides protection from pathogens, but also underlies 
diseases such as autoimmunity and allergy. As such, the ability to mount 
protective immune responses while preventing the development of autoimmunity 
is essential for continued health. Four attributes of the immune response in 
vertebrates are key to achieving these goals. These are (1) recognition of an 
incipient infection, (2) control/clearance of the infection via immune effector 
functions, (3) regulation to prevent/limit immune mediated damage to the host, 
and (4) establishment of immunological memory that provides durable protection 
from reinfection.  
 When a pathogen breaches host defenses, including barriers such as the 
skin and mucus membranes, innate immune mechanisms provide a rapid first-
line of defense. The innate immune system includes myeloid cells such as 
granulocytes, dendritic cells, macrophages, and mast cells, that rapidly sense the 
pathogen. This is mediated by germ-line encoded pattern recognition receptors 
(PRRs) that recognize evolutionarily conserved pathogen associated molecular 
patterns (PAMPs) expressed by microbes1, as well as damage associated 
molecular patterns (DAMPs) that are released from cells following damage and 
death2. Engagement of PRRs by PAMPs and/or DAMPs activates cells of the 




differentiative programs that  in turn will instruct the effector choices undertaken 
by the cells participating in the adaptive immune response3. 
 While the innate immune system generates a rapid response by 
recognizing broadly conserved molecular moieties, the adaptive immune system 
generates a response that is finely tailored to unique molecular determinants of 
the pathogen. Many key aspects of the adaptive response can be explained by 
Burnet’s clonal selection paradigm. Fundamental to Burnet’s theory is that each 
lymphocyte expresses antigen receptors of a single specificity, and that 
occupation of these receptors induces cells to respond and divide, thus 
producing daughter cells with the same specificity as the original responding cell.  
1.2 B Lymphocyte Development 
In adults, B cell development begins in the bone marrow with pluripotent 
hematopoietic stem cells that generate multipotent progenitor cells, which have 
lost their potential as self-renewing stem cells, but can give rise to both lymphoid 
and myeloid cells. These multipotent progenitor cells express the cell surface 
receptor tyrosine kinase FLT3, and signaling through this receptor leads to 
differentiation into the common lymphoid progenitor (CLP)4, 5, 6, 7. Some CLP 
progeny then differentiate into a pro-B cell, which is the first cell type firmly 
committed to the B cell lineage. These cells initiate the process of 
immunoglobulin (Ig) gene rearrangement, which ultimately leads to expression of 
a functional B cell receptor (BCR). The first stage of Ig gene rearrangement 




diversity (D) gene segment to a joining (JH) gene segment8. In the late pro-B cell, 
a variable (VH) gene segment is joined to the previously generated DJH segment. 
This can generate a productive VHDJH segment that is expressed as part of the 
pre-BCR, together with a surrogate light chain (SLC)9. Proper VHDJH 
rearrangement and pairing with the SLC is required for transit to the next stage of 
B cell development, and roughly half of pro-B cells fail to successfully complete 
this process and are eliminated10. In the next stage of B cell development, the 
large pre-B cell undergoes extensive proliferation, expanding 30-60 fold. The 
developing B cell then becomes a resting small pre-B cell11, 12, 13. The small pre-B 
cell once again expresses RAG and rearranges the germline light chain 
sequence to generate a light chain VJ segment14, 15. After a productive light chain 
VJ rearrangement, the small pre-B cell becomes an immature B cell and 
expresses a full IgM BCR on its surface with both a rearranged heavy and light 
chain. The IgM-expressing B cell is subject to positive and negative selection 
based on BCR signal strength in order to eliminate autoreactive clones and 
identify B cells with signaling-competent receptors. Strikingly, as many as 75% of 
immature B cells are initially autoreactive16, 17. Given this stringent selection, only 
10% of immature B cells exit the bone marrow into the peripheral lymphoid 
organs. Here, they undergo further selection and more than half of the remaining 




1.3 Lymphocyte Effector Subsets 
Following antigen encounter and activation, both T and B lymphocytes 
undergo further differentiation into distinct effector and memory subsets.  For 
example, CD4 T cells differentiate into distinct effector lineages characterized by 
unique cytokine production profiles and lineage-specific transcription factors that 
are required for their differentiation23. These distinct effector lineages have 
differing functions, and their proper regulation is key to initiating and maintaining 
a protective immune response, as inappropriate effector lineage commitment 
leads to failed pathogen clearance and/or autoimmune and inflammatory 
pathologies24. The cytokine milieu, as well as T cell receptor (TCR) signaling and 
costimulation, determine commitment to a given effector lineage. Similarly, CD8 
T cells include distinct effector subsets with specialized functions and distinct 
transcription factor profiles. These can differ in terms of tissue residency and 
recirculation, which is important for tissue surveillance and protection from 
reinfection25. Importantly, resident memory T cells (Trm) fail to recirculate and 
remain tissue resident, as demonstrated through parabiosis experiments26, 27, 28. 
Most of these Trm are not exposed to circulation as demonstrated by a failure to 
label following intravenous fluorescent antibody injection29. These Trm are 
important for protective immunity against local reinfection30. For example, in a 
local vaccinia virus re-challenge model, mice with skin resident Trm rapidly 
cleared reinfection whereas mice lacking Trm failed to control the virus despite 




While the importance of effector T cell subsets with distinct tissue residency 
and recirculation properties is appreciated, a similar understanding of the breadth 
of memory B cells is ongoing. One way to stratify B cells into various effector 
subsets is on the basis of heavy chain isotype. The BCR heavy chain has five 
main isotypes; delta, mu, gamma, alpha, and epsilon. These heavy chain 
isotypes pair with either a kappa or lambda light chain to form IgD, IgM, IgG, IgA, 
or IgE. Furthermore, the IgG isotype can be split into four subtypes; IgG1, 
IgG2a/c (with IgG2a present in BALB/c and IgG2c in C57BL/631), IgG2b, and 
IgG3 in mice and IgG1, IgG2, IgG3, and IgG4 in humans. Similar to T cell effector 
lineages, the cytokine milieu along with receptor signaling are key drivers of class 
switch recombination decisions with the various BCR isotypes serving differing 
roles in an immune response32, 33. Isotype-specific Fc receptors are expressed on 
a range of hematopoietic origin cells. These Fc receptors can be either activating 
or inhibitory and as such the Ig isotype has important effects on cell activation 
and behavior. These Fc receptor interactions can regulate multiple effector 
responses including antibody-dependent cytotoxicity, phagocytosis, and 
inflammatory mediator release33.  
However, heavy chain isotype is not the only way in which mature B cells can 
be divided into distinct subsets. Following antigenic stimulation, B cells can be 
recruited into a germinal center (GC) response. These GC B cells can undergo 
robust proliferation, with the magnitude of T cell help being an important 
determinant of the extent of division. GC B cells acquire point mutations in their 




selected for survival. These high affinity GC B cells go on to become memory B 
cells or plasma cells and can even participate in further rounds of GC selection34, 
35. These GC derived memory B cells may be primed for rapid differentiation into 
antibody secreting cells upon reexposure36, 37.  
Similar to T cells, mature B cells can be divided on the basis of key lineage 
commitment transcription factor expression38, 39. The transcription factor T-bet is 
characteristic of Age Associated B Cells (ABCs) and will be the focus of the work 
discussed here.  
1.4 T-bet+ Age Associated B Cells 
While previous work demonstrated that T-bet expression in B cells is 
important for class switching to the IgG2a/c isotype40, the discovery of a unique B 
cell subset characterized by T-bet expression can be credited to the Cancro and 
Marrack laboratories41, 42. Despite using different criteria to define this novel B 
cell population, both observed an accumulation of these cells in mice with 
increasing age and termed them Age Associated B Cells (ABCs). Subsequent 
work has demonstrated that they are largely overlapping populations41, 42. 
Furthermore, Rubtsov et al. observed that these cells accumulated earlier in 
females of various autoimmune prone mouse strains and that a similar cell 
population could be found in elderly women with autoimmune conditions42.  
ABCs display several unique characteristics. They are refractory to BCR 
crosslinking, thus distinguishing them from follicular B cells which robustly 




and transitional B cells, which die upon BCR crosslinking41, 43. ABCs proliferate in 
response to endosomal Toll Like Receptor (TLR) stimulation. This proliferation 
can be enhanced by the addition of BCR stimulation, showing that while ABCs do 
not proliferate in response to BCR crosslinking alone, the BCR retains some 
signaling capabilities. However, ABCs fail to proliferate in response to TLR4 
stimulation as provided by the ligand lipopolysaccharide (LPS), further 
distinguishing them from other mature B cell subsets such as MZ B cells which 
robustly expand following LPS treatment41, 43.  
While ABCs accumulate with age, this does not reflect the emergence of a 
distinct precursor population in aged bone marrow. Sublethal irradiation with 500 
cGy in aged mice results in the successful ablation of most peripheral B cell 
pools including ABCs, follicular B cells, and MZ B cells. Following irradiation, the 
ABC pool fails to rapidly autoreconstitute despite the rapid reestablishment of the 
follicular and MZ B cell pools. Additionally, adoptive transfer of splenic follicular B 
cells gives rise to ABCs within 30 days of transfer and donor or recipient age has 
no impact on the formation of these donor derived ABCs. Interestingly, cells with 
an ABC phenotype preferentially arise from the fraction of donor cells undergoing 
the most robust proliferation following adoptive transfer. While ABCs express the 
BAFF/BLyS receptors BAFFr (BR3) and TACI, they do not rely on BAFF 
signaling for their survival as ABC numbers are not impacted by treatment with 





A large portion of ABCs express the transcription factor T-bet42. T-bet, or T-
box containing protein expressed in T cells, is a transcription factor encoded by 
the Tbx21 gene. It was first described as a master regulator controlling the 
commitment of CD4 T cells to a Th1 effector lineage44. Subsequently, it has been 
shown to be important for the development, survival, and function of various 
innate and adaptive immune cell types45. Its role in B cells has gained increasing 
appreciation as T-bet expressing B cells are associated with a range of infections 
46, 47, 48, 49, 50, 51, 52, 53, 54, 55 and autoimmune pathologies in both mice and 
humans42, 56, 57, 58, 59. T-bet+ B cells likely play an important role in protective 
immune responses as mice lacking T-bet expression in B cells show impaired 
viral control51, 55. 
Requirements for T-bet Expressing B Cell Formation 
 T-bet expression in B cells was first observed after in vitro treatment of 
splenic B cells with CD40, interleukin (IL) 12, and IL-1844. Subsequent work 
demonstrated that T-bet promotes B cell isotype switching to IgG2a/c40.  T-bet 
expression is robustly induced in vitro after treatment of follicular B cells with 
either interferon gamma (IFNγ) or IL-21 in the presence of TLR7 or TLR9 
agonists60. The addition of IL-4 has differential effects on T-bet induction 
depending on whether it is added to IFNγ or IL-21 stimulated B cells: the addition 
of IL-4 to IL-21 stimulated follicular B cells blocks T-bet induction whereas 
addition of IL-4 to IFNγ stimulated B cells preserves and possibly even enhances 




STAT6 dependent and cell intrinsic. STAT6 knockout follicular B cells co-cultured 
with wildtype follicular B cells still upregulate T-bet in response to IL-21 and IL-4 
treatment in the presence of a TLR9 agonist. However, cocultured wildtype cells 
failed to induce T-bet in response to this combination of stimuli. A large portion of 
IL-21 driven T-bet+ B cells express the integrin CD11c whereas IFNγ driven T-
bet+ B cells are uniformly CD11c negative60. Together, these results imply that 
IFNγ and IL-21 utilize different pathways to drive T-bet induction, and that T-bet 
expression alone is insufficient to drive CD11c expression. Thus, T-bet 
expression is unlikely to be a simple on/off switch but instead can be driven 
through multiple inductive pathways. A similar pattern of T-bet induction can be 
observed in vivo, as B6 mice, which show a strong TH1 skewing and resultant 
high levels of IFNγ61, have much higher proportions of T-bet expression in GC 
and memory B cells than BALB/c mice, which have a TH2 bias and associated 
high IL-4 levels61. Infection with the PR8 strain of influenza, which leads to a TH1 
skewed response with robust IFNγ, IL-21, and IL-4 production by responding TFH 
cells62, results in a strong T-bet+ GC B cell response in wildtype C57BL/6 but not 
IFNγ knockout mice, despite a similar magnitude in overall GC B cell response. 
The T-bet+ GC B cell response is rescued in IL-4/ IFNγ double knockout mice, 
despite an overall decrease in the GC B cell response. Infection of C57BL/6 mice 
with the TH2 biased pathogen H. polygyrus, which leads to IL-21 and IL-4 
production by TFH cells in the absence of IFNγ63, fails to induce T-bet expression 




CD11c expression in GC B cells. This is not due to increased IFNγ in IL-4 
knockout mice mice, as the T-bet+ CD11c+ GC B cell response is observed in IL-
4/ IFNγ double knockout mice60. 
T-bet Expressing B Cells in Health and Disease 
The first demonstration of T-bet+ B cells in pathogen-driven immune 
responses was provided by the Winslow lab, who showed that IgM+ CD11c+ 
splenic plasmablasts64 and memory B cells65 emerge follow Ehrlichia muris 
infection in mice. Later work showed that these cells express T-bet66. T-bet+ B 
cells emerge following viral infections as first demonstrated by the identification 
of T-bet+ CD11c+ B cells following gamma herpes virus 68 infection. These cells 
produce virus specific IgG2a and are important for maintaining reduced virus 
titers55. Furthermore, T-bet+ B cells are important in controlling lymphocytic 
choriomeningitis virus (LCMV) infection, as T-bet+ B cells are required for LCMV 
specific IgG2a production. While not required for control of acute LCMV infection, 
T-bet+ B cells are required for viral control during chronic infection. Serum 
transfer of LCMV specific IgG2a into infected mice with B cells lacking T-bet was 
unable to control chronic LCMV viral loads, indicating that T-bet+ B cells have 
important roles in viral control beyond IgG2a production51. 
These results indicate that T-bet+ B cells are likely a memory B cell 
population. They persist long term following viral infection and clearance, as 
evidenced by the sustained presence of antigen specific T-bet+ B cells in mice 




demonstrated the persistence of T-bet+ B cells in aviremic HIV patients after 
years of successful antiretroviral therapy52.  
T-bet+ B cells are also important in autoimmunity. T-bet+ B cells or B cells with 
T-bet associated phenotypes can be observed at increased frequencies in 
patients with a wide range of autoimmune pathologies, such as lupus, multiple 
sclerosis, rheumatoid arthritis, Crohn’s disease, celiac disease, common variable 
immune deficiency, Sjogren’s syndrome, and hepatitis associated mixed 
cryoglobulinemia56, 59, 67, 68, 69, 70, 71, 72, 73, 74, 75. 
1.5 Scope 
T-bet+ B cells are induced and persist in response to pathogen challenge, but 
outstanding questions regarding their kinetics, residency and function remain. In 
chapter 2, we examined the emergence and persistence of T-bet+ B cells 
following influenza infection and tested their contribution to the humoral 
response. As T-bethigh B cells display progressive splenic restriction, we tested 
their residency using parabiosis. In chapter 3, we further investigated the fate of 
T-bet+ B cells by examining their ability to differentiate into other cell types, 
including plasma cells. We found that spleen resident T-bethigh memory B cells 
likely differentiate into a circulating population that eventually gives rise to plasma 







CHAPTER 2: The Emergence, Maintenance, and Residency of T-bet+ B Cells 
in an Influenza Response 
2.1 Summary 
 In this section, we track the emergence and maintenance of influenza 
hemagglutinin (HA) specific B cells following influenza infection in mice. Using a 
T-bet ZsGreen reporter mouse strain, we show that a portion of HA-specific B 
cells express the transcription factor T-bet. While T-bet- HA-specific B cells can 
be found in both the spleen and draining mediastinal lymph nodes (LNs) long 
term following infection, T-bet+ memory B cells are largely restricted to the spleen 
at memory time points and are absent from the lymphatics. Using parabiosis, we 
demonstrate that while T-bet- and T-betlow HA-specific B cells traffic and are 
found in the spleens of both partner mice, T-bethigh HA-specific B cells are 
restricted to the spleen of the previously infected partner, indicating that they are 
sessile splenic residents. T-bet+ B cells are important in generating influenza 
specific IgG2a/c titers as these are greatly reduced in mice lacking T-bet 
expressing B cells. Furthermore, HA stalk titers are nearly absent in mice without 
T-bet+ B cells. While HAI titers are similar between all genotypes at day 15 post 
infection, they are significantly reduced by day 40 in mice lacking T-bet 
expression in B cells, indicating that T-bet is likely required for sustained 





The importance of T-bet in immune responses was first recognized in 
studies from the Glimcher lab, that showed T-bet is a key transcription factor in 
driving CD4 T cell commitment to a T helper 1 (Th1) cell fate44. Later work 
showed that T-bet is involved in the development and effector functions of 
various innate and adaptive immune cell types45. As such, there is an increasing 
appreciation of T-bet as a key feature of immune cells in type 1 immune 
responses.  
T-bet plays an important role in protection, recovery, and/or pathogen 
burden in a range of infections. T-bet deficient mice show an increased incidence 
and severity of septic arthritis and increased renal bacterial counts following 
Staphylococcus aureus infection76. Mice lacking T-bet are more susceptible to 
aerosol or IV Mycobacterium tuberculosis infection as demonstrated by 
decreased survival and increased bacterial burdens in the lungs, liver, and 
spleen77. Furthermore, T-bet knockout mice have decreased survival and 
increased splenic bacterial counts after Salmonella typhimurium infection78. In 
terms of Francisella tularensis infection, T-bet knockout mice were more 
susceptible to death, even at lower doses than wildtype mice, and showed 
increased bacterial burdens in the spleen, liver, and lungs regardless of route of 
infection. They also displayed an increased susceptibility to re-challenge, as 
evidenced by increased death following high dose intra-nasal secondary infection 




studies demonstrating a link between strength of Francisella vaccine engendered 
protection and magnitude of upregulation of T-bet expression80. However, not all 
immune protection following bacterial infection relies on T-bet. T-bet deficient 
mice do not show impaired Listeria monocytogenes bacterial control and 
clearance during the innate or adaptive phases of the response81. In terms of the 
intracellular protozoan Leishmania major, T-bet-/- C57/BL6 mice were more 
susceptible than their wildtype littermate controls and showed a similar failure to 
resolve lesions and control pathogen burden as the susceptible Th2 biased 
BALB/c mouse strain82.  
Furthermore, T-bet is important in controlling certain viral infections. Mice 
lacking T-bet had increased viral titers, accelerated disease onset, and impaired 
survival following genital Herpes Simplex Virus Type 2 infection. This impaired 
protection extended to secondary responses as T-bet-/- mice receiving an 
attenuated virus vaccine had impaired control of viral replication and increased 
disease severity, viral titers, and death after secondary infection83. Mice lacking 
T-bet were more susceptible to Vaccinia virus infection as evidenced by 
decreased survival, increased weight loss, and greater persistence of viral 
titers84. While T-bet deficient mice did not display impaired viral clearance 
following rhinovirus infection, they failed to generate robust antiviral IgG2c titers 
and displayed exacerbated viral mediated airway inflammation as evidenced by 
increased airway eosinophilia and mucus hypersecretion85.   
While T-bet is clearly a key mediator in the response to a variety of 




such, the observed effects may be related to a failure to generate Th1 polarized 
CD4 T cells and therefore decreased IFNγ production. The specific role of T-bet 
expressing B cells in immune protection remains less clear and may be 
complicated by B cell/T cell interactions such that T-bet deficiency in either T 
cells or B cells may have effects on other cell types. Research from the Wherry 
lab suggests that T-bet expressing B cells may be important in the control of 
chronic viral infections, as mice lacking T-bet in B cells are unable to control 
chronic LCMV infection51. It remains unknown whether T-bet expression can be 
used to stratify memory B cells into subsets with distinct characteristics and 
functions.  
In this chapter, we investigate the kinetics, anatomic residency, trafficking, 
and function of T-bet+ B cells in mice following influenza infection. We show that 
HA-specific B cells can be divided into T-bet-, T-betlow, and T-bethigh populations. 
Whereas all three populations are initially observed in the spleen, lungs, and 
draining LNs, the T-bethigh population is restricted to the spleen at memory 
timepoints and remains resident following parabiosis whereas the T-bet- and T-
betlow populations recirculate and can be found in the spleen of the partner 
mouse. We demonstrate that B cell specific T-bet expression is required for the 
development of HA-specific IgG2c titers and stalk specific antibody and durable 
neutralizing antibody titers. Together, these findings show that T-bet expression 




used to delineate memory B cell populations that differ in terms of residency, 
recirculation, and functional properties.        
2.3 Results 
2.3.1 Emergence and Maintenance of HA-Specific T-bet+ B Cells in the Spleen 
 While previous studies established the presence of T-bet+ HA-specific B 
cells in the spleen 100 days post PR8 influenza infection47, we wanted to 
undertake a detailed study of the kinetics of the emergence and maintenance of 
these cells. We utilized Tg(Tbx21-ZsGreen)E3ZJfz mice (hereafter referred to as 
T-bet ZsGreen) that are transgenic for a bacterial artificial chromosome (BAC) 
that reports T-bet expression using the fluorescent protein ZsGreen86. We 
infected T-bet ZsGreen reporter mice with the 30 TCID50 of influenza A/Puerto 
Rico/8/1934 (PR8) and verified successful infection via weight loss. As expected, 
mice initially lost weight following infection reaching the nadir at day 9 and then 
recovered over the following weeks (Figure 1A). We first wanted to determine the 
number and T-bet expression status of HA-specific B cells at various timepoints 
following infection. We used a double labelling technique in which biotinylated 
PR8 hemagglutinin was coupled to either Brilliant Violet 421 (BV421) or Alexa 
Flour 647 (AF647) fluorescently labelled streptavidin molecules in order to create 
a HA-biotin streptavidin “tetramer”. HA-specific B cells were identified as a 
double positive population binding to both of the HA-biotin streptavidin 
“tetramers”. This double labelling strategy greatly improved the specificity of 




As expected, prior to infection HA-specific B cells are present at very low 
precursor frequencies. This is in line with prior estimates of ∼1/50,000 splenic B 
cells (Figure 1B)87. For future analysis, we excluded this naïve primary B cell pool 
by focusing on IgD- B cells (Figure 1C). Following infection, the HA-specific B cell 
population undergoes rapid expansion, reaching peak numbers at 15 days post 
infection. The HA-specific splenic B cell numbers then contract, but remain 
present at higher frequencies than observed prior to infection for at least 100 
days (Figure 1E). 
We next assessed the T-bet expression status of these HA-specific B 
cells. Prior to infection, HA-specific B cells were uniformly negative for the 
transcription factor T-bet (Figure 1B). By day 7 post-infection, about 20% of HA-
specific B cells are positive for T-bet, and a portion of the highest T-bet 
expressing cells express the integrin CD11c. We stratified these T-bet+ B cells 
into T-bethigh and T-betlow populations. Using qPCR for Tbx21 expression, we 
showed that both T-bethigh and T-betlow populations express increased T-bet 
levels as compared to T-bet- or CD19Cre/WT T-betfl/fl B cells (Figure 1D). This 
indicates that both T-bethigh and T-betlow B cells represent bona fide T-bet 
expressing B cell populations. Furthermore, we compared the T-bet ZsGreen 
expression levels observed in these populations to that seen in canonical T-bet+ 
CD21- CD23- ABCs (Figure 1C). At all timepoints analyzed following PR8 




T-betlow, and T-bet- populations, indicating that antigen specific T-bet+ B cells 










T-bet-ZsGreen reporters were intranasally infected with 30 TCID50 influenza 
A/Puerto Rico/8/1934 (PR8) (A) Weight loss and recovery from PR8 influenza 
infection in T-bet-ZsGreen mice compared to PBS-treated controls. (B) 
Fluorescently-conjugated PR8 hemagglutinin (HA) detects the precursor 
frequency of HA-specific (HA+) B cells in naïve T-bet-ZsGreen mice, which are 
uniformly T-bet-. The naïve precursor frequency per 100,000 B cells is plotted. 
(C) Gating scheme for the identification of HA-specific B cells in T-bet-ZsGreen 
mice and subsetting into T-bet-, T-betlow, and T-bethigh populations via flow 
cytometry. C57Bl/6 mice are included in the T-bet-ZsGreen expression plot as a 
control. (D) Tbx21 expression in sorted T-bet-, T-betlow, and T-bethigh
 
B cell 
subsets via qPCR. CD19+ B cells were sorted into the corresponding subsets 
according to ZsGreen expression (C), and RNA was isolated and cDNA prepared 
for qRT-PCR analysis. (E) Fluorescently-conjugated PR8 hemagglutinin (HA) 
detects HA-specific B cells, and T-bet-ZsGreen expression in HA-specific B cells 
resolves T-bet-, T-betlow, and T-bethigh subsets in the spleen at acute (day 15) and 
memory (day 100) timepoints. Number of HA-specific B cells in the spleen at 
various time points after infection (top), and proportions of HA-specific B cells 
that are T-bet-, T-betlow, and T-bethigh (bottom). Data in (B), (D), and (E) are 
plotted as mean ± SEM. **p<0.01 Data in (E) are representative of or compiled 
from 2 independent experiments with at least 3 mice per experiment. HA-specific 
B cells were identified as live, singlet, DUMP-, B220+, CD19+, IgD- cells, HA-





2.3.2 Germinal Center and Memory Marker Expression in Splenic HA-Specific B 
Cells 
 We wanted to further define HA-specific T-bet+ B cells to determine if they 
differed from T-bet- HA-specific B cells in terms of GC or memory marker 
expression. We performed surface staining for GL7, CD95 (FAS), CD38, CD80, 
PD-L2, and CD73 at various timepoints following infection. GC B cells are 
positive for peanut agglutinin (PNA) binding and typically express increased 
levels of GL7 and CD95, and decreased levels of CD38 when compared to naïve 
follicular B cells88, 89, 90. For our analyses, we classified GL7+ CD38- B cells as 
GC B cells and GL7- CD38+ B cells as memory B cells and analyzed both the 
absolute numbers and relative frequencies of these populations within HA-
specific B cells (Figure 2A). To further demonstrate the validity of this gating 
strategy, we demonstrated that there was good correspondence between GL7 
and other GC markers such as CD95 at all measured timepoints (Figure 2B). By 
day 7 post PR8 infection, a fraction of HA-specific B cells are beginning to 
express a GC phenotype as evidenced by increased GL7 expression; however a 
large portion of HA-specific B cells have not yet assumed this phenotype (Figure 
2A). The T-bet+ HA-specific B cell fraction likely enters the GC response earlier 
than the T-bet- subset, as a higher portion of T-bet+ B cells have upregulated 
GL7 by day 7 post infection (Figure 2A). Regardless, a large fraction of these 
cells have not yet downregulated CD38, consistent with a pre-GC phenotype89, 91 
(Figure 2A). By day 15, the vast majority of T-bet+ and T-bet- B cells have 




levels (Figure 2A). This same phenotype is observed at day 22, but by day 40 a 
large portion of HA-specific B cells are exiting the GC as they have begun 
downregulating GL7 while CD38 is beginning to increase (Figure 2A). The T-bet+ 
HA-specific B cells likely exit the GC earlier than the T-bet- B cells as a higher 
portion of the T-bet+ B cells no longer express the GC phenotype at day 40 
(Figure 2A). By day 100, virtually all T-bet+ and T-bet- HA-specific B cells fail to 
express increased levels of GL7, indicating that the GC response has subsided 
(Figure 2A). At later timepoints, a large portion of T-bet+ and T-bet- HA-specific B 
cells have upregulated CD73, and this is most pronounced at day 100 (Figure 
2C). Increased CD73 expression is consistent with a GC origin for most T-bet+ 
and T-bet- HA-specific memory B cells91, 92.  
 In a broad sense, memory B cells can be defined as B cells that have 
responded to antigen, returned to a resting state, and remain present in 
expanded numbers indefinitely post exposure. These cells should be able to 
participate in the context of a re-challenge; contributing to a rapid memory 
response93, 94. Beyond this, memory B cells express a defined pattern of surface 
markers as described by Shlomchick and others36. By day 40, most T-bet+ B cells 
are post GC and express memory markers whereas a large portion of T-bet- B 
cells still show a GC phenotype and have not yet upregulated memory markers. 
The memory marker CD80 first rises during acute infection and undergoes a 
further increase starting at day 40 post infection (Figure 2C). CD73 and PD-L2 
stay at low levels on HA-specific B cells until days 15-22 when they start to 




CD80, CD73, and PD-L2 can be seen at their highest levels in both T-bet+ and T-
bet- HA-specific B cells at day 100 post infection, consistent with establishment of 
a stable memory B cell pool (Figure 2C). Overall, T-bet+ and T-bet- HA-specific B 
cells have a shared GC and memory marker expression pattern, although T-bet+ 




Figure 2: Germinal Center and Memory Marker Expression of Splenic HA-
Specific B Cells 
 T-bet-ZsGreen reporters were intranasally infected with 30 TCID50 influenza 




(HA+) germinal center (GC) B cell (GL7+CD38-), memory B cell (MBC) (GL7-
CD38+), and pre-GC B cell (CD38+GL7+) subsets; concatenated flow plots 
(bottom) depict CD38 and GL7 expression of T-bet+ (pooled T-betlow and T-
bethigh; green) and T-bet- (purple) HA-specific B cells at each time point (bottom). 
Line plots (top) depict number of HA-specific GC B cells and MBCs separated by 
T-bet expression phenotype over time (B) Expression of GL7 and CD95 on T-bet- 
and T-bet+ splenic HA-specific B cells at the indicated time points post PR8 
infection. (C) Expression of memory markers (CD80, PD-L2, CD73) in T-bet+ 
(green) and T-bet- (purple) splenic HA-specific MBCs (GL7-CD38+) and naive 
follicular B cells (IgD+; grey). Data in (A), (B), and (C) are representative of 2 
independent experiments with at least 3 mice per experiment. Data in (A) are 
plotted as mean ± SEM. HA-specific B cells were identified as live, singlet, 
DUMP-, B220+, CD19+, IgD- cells, HA-BV421+, HA-AF647+ cells. DUMP gate 








2.3.3 Tissue Localization of HA-Specific B Cells 
 In addition to investigating the dynamics of splenic T-bet+ and T-bet- HA-
specific B cells following influenza infection, we wanted to track the appearance 
of these cells in other tissues. As expected, following influenza infection we 
observed a rapid expansion of HA-specific B cells in the mediastinal LNs, lungs, 
and blood (Figure 3A). HA-specific B cells were especially prevalent in the 
mediastinal LNs, often reaching frequencies as high as 5% of total IgD- B cells 
(Figure 3A). As seen in the spleen (Figure 1D), after resolution of influenza 
infection, these HA-specific B cells underwent contraction, but remained present 
long term at numbers and frequencies higher than those seen prior to infection 
(Figure 3A). The kinetics showed some variance among tissues, with HA-specific 
B cell numbers in the mediastinal LNs and blood peaking at day 22, whereas in 
the spleen and lungs these numbers reached their highest point at day 15 post 
infection (Figures 1D; 3A). Strikingly, while T-bet- and T-bet+ B cells remained 
relatively constant in their proportions throughout the immune response in the 
spleen, comprising about a quarter of HA-specific B cells (Figure 1D), a different 
pattern was observed in the mediastinal LNs and lungs. While early on in the 
response T-bet+ B cells were evident, their contribution waned with time, a trend 
particularly obvious with the T-bethigh HA-specific B cells (Figure 3A). Despite 
very low HA-specific B cell numbers in the lungs at day 7 post infection, nearly all 
these cells expressed high levels of T-bet (Figure 3A). By day 15, the number of 
HA-specific B cells in the lungs had greatly increased and roughly half of these 




undergone extensive contraction and very few of these cells expressed high 
levels of T-bet (Figure 3A). In the mediastinal LNs, at day 7 post infection roughly 
75% of HA-specific B cells expressed T-bet and slightly more than a third of 
these could be classed as T-bethigh (Figure 3A). By day 15, none of the HA-
specific B cells were T-bethigh and the T-betlow population had also significantly 
waned (Figure 3A). A similar pattern was observed in the blood, albeit with 
somewhat delayed kinetics (Figure 3A). While HA-specific B cells are observed 
long term at increased frequencies in the spleens, mediastinal LNs, lungs, and 
blood of infected mice, the T-bethigh population persists long term in the spleen 
and not in other tissues. Low numbers of HA-specific B cells were observed in 
pooled peripheral (superficial cervical, axillary, brachial, and inguinal) and 
mesenteric LNs, but this contribution to the response was much smaller than that 
observed in the spleen and mediastinal LNs with the T-bethigh fraction nearly 






Figure 3: Tissue Restriction of T-bet+ HA-Specific B Cells 
T-bet-ZsGreen reporters were intranasally infected with 30 TCID50 influenza 
A/Puerto Rico/8/1934 (PR8) (A) Fluorescently-conjugated PR8 hemagglutinin 
(HA) detects HA-specific (HA+) B cells, and T-bet-ZsGreen expression in HA-
specific B cells resolves T-bet-, T-betlow, and T-bethigh subsets in the mediastinal 
lymph nodes (medLN) and lungs at acute (day 15) and memory (day 100) 




and blood at different time points after infection (left), and proportions of HA-
specific B cells that are T-bet-, T-betlow, and T-bethigh in each tissue (right). The 
number of HA-specific B cells in blood was estimated by calculating their 
frequency per 100,000 B cells, and proportions of T-bet-defined subsets in blood 
were calculated after concatenation due to low cell number. (B) Number of HA-
specific B cells in peripheral and mesenteric lymph nodes (LN) by T-bet 
expression phenotype at different time points after infection. Data in (A) and (B) 
are representative of or compiled from 2 independent experiments with at least 3 
mice per experiment and are plotted as mean ± SEM. HA-specific B cells were 
identified as live, singlet, DUMP-, B220+, CD19+, IgD- cells, HA-BV421+, HA-






2.3.4 Tissue Residence of HA-Specific B Cells is Stratified by T-bet Expression  
The splenic restriction of T-bet+ HA-specific B cells at memory timepoints 
raised the question of whether this population might be splenic resident. In order 
to investigate this question, we undertook a parabiosis based approach. A T-bet 
ZsGreen reporter mouse infected 40+ days prior with PR8 influenza was 
surgically joined to an uninfected congenic partner. These mice established a 
shared circulatory system after which they were euthanized and the presence of 
T-bet+ and T-bet- HA-specific B cells was analyzed in each partner. As virtually 
all HA-specific memory B cells arise in previously infected T-bet ZsGreen 
partner, we reasoned that the presence of these cells in the B6.SJL partner 
suggests that they are a recirculating population. As a confirmation of successful 
anastomosis and establishment of a shared circulatory system, sequential tail 
bleeds were performed on both partner mice. By day 7 post-surgery, we 
observed mixing of CD45.1 and CD45.2 B cells in the blood of both partner mice, 
with these populations achieving stable proportions between partners by day 14 
(Figure 4A). This is in accordance with previous studies calculating complete 
blood exchange occurring between parabiotic partners within 12 days of 
surgery95. As such, parabiosed pairs were euthanized at ≥ 17 days post-surgery. 
Similar frequencies of CD45.2+ IgD+ B cells, which we expect to recirculate freely 
between partners, were observed in the spleen, lungs, and mediastinal LNs of 
each partner, suggesting equilibration of recirculating B cells within 17 days of 




HA-specific IgD- memory B cells were identified in the spleen of both 
partners, and nearly all of these cells were CD45.2+, consistent with their origin in 
the previously infected T-bet ZsGreen partner (Figure 4C). Within the HA-specific 
IgD- memory B cell population, T-bet- and T-betlow B cells were identified in the 
spleens of both partners. While the number of cells in both of these populations 
was significantly lower in the uninfected B6.SJL partner (Figure 4D), this 
difference was no longer apparent after normalizing for differing numbers of 
CD45.2+ B cells in the spleens of the two partner mice (Figure 4E). This indicates 
that T-bet- and T-betlow HA-specific B cells are likely a freely recirculating 
population. Importantly, T-bethigh HA-specific B cells were virtually absent from 
the spleen of the uninfected B6.SJL partner, despite being present in the spleen 
of the previously infected T-bet ZsGreen partner (Figure 4D; 4E). A similar trend 
showing a selective failure of HA-specific T-bethigh B cells to recirculate to the 
partner spleen can be appreciated when looking at the portion of HA-specific B 
cells that belong to the T-bethigh, T-bet-, or T-betlow population (Figure 4F). This 
near absence of T-bethigh HA-specific B cells in the B6. SJL partner spleen was 
apparent even when data was concatenated from 7 parabiotic pairs (Figure 4G). 
To confirm that ZsGreen-expressing cells were not being rejected in the 
B6.SJL mice, we measured frequencies of CXCR3+CD8+ lymphocytes, which 
highly express T-bet-ZsGreen, and found similar frequencies of these cells in 
both partners (Figure 4H). T-betlow HA-specific B cells were present in the 
spleens of both mice (Figure 4D; 4E; 4F), together suggesting that broad 




studies that failed to detect an immunogenic response to ZsGreen protein in 
C57Bl/6 mice96. Taken together, these findings identify splenic T-bethigh HA-
specific B cells as a tissue-resident memory pool.  
We next investigated whether HA-specific memory B cells show evidence 
of residency in the mediastinal LNs and lungs, the other primary locations of 
influenza memory B cells, as others recently demonstrated97. We identified 
significant IgD- HA-specific memory B cell populations in the mediastinal LNs and 
lungs of the previously infected partner, but these cells were absent in the 
uninfected partner, suggesting they are tissue resident populations (Figure 4I; 
4J). Interestingly, nearly all mediastinal LN and lung-localized HA-specific B cells 
were negative for T-bet (Figure 4K; 4L). However, this residency phenotype may 
reflect persistent GCs as GL7+ CD38- HA-specific B cells are observed in the 
mediastinal LNs as much as 100 days post infection (Figure 4M). Together, 
these results demonstrate that tissue-resident HA-specific B cell memory is 
anatomically compartmentalized, comprised of T-bethigh B cells in the spleen and 





Figure 4: T-bet expression resolves spleen resident versus recirculating 
memory B cell pools 
(A) T-bet-ZsGreen reporters (CD45.2+; ≥ 40 days post infection) and uninfected 
B6.SJL (CD45.1+) were surgically conjoined and showed evidence of blood 




euthanized at ≥ 17 days post-surgery for analysis. (B) Frequencies of naïve 
follicular (IgD+) B cells expressing CD45.2 in lymphoid and non-lymphoid tissues 
from each parabiosis pair. (C) Identification of HA-specific IgD- B cells expressing 
either CD45.1 or CD45.2 in parabiosis partners. (D) Numbers of T-bet-, T-betlow, 
and T-bethigh HA-specific (HA+) splenic memory B cells (MBCs) in T-bet-ZsGreen 
(red) and B6.SJL (black) partners. (E) Numbers of T-bet-, T-betlow, and T-bethigh 
HA-specific splenic memory B cells per 106 CD45.2+ B cells in T-bet-ZsGreen 
(red) and B6.SJL (black) partners. (F) Percentage of splenic HA-specific memory 
B cells that are T-bet-, T-betlow, or T-bethigh in parabiosis partners. (G) 
Identification of T-bet-ZsGreen reporter-derived (CD45.2+) T-bet-, T-betlow, and T-
bethigh HA-specific memory B cells in spleens of T-bet-ZsGreen and B6.SJL 
partners; data concatenated from 7 pairs. (H) The percent of splenic CD45.2+ 
CD8+ T cells that are T-bet-ZsGreen+ CXCR3+ in each partner after ≥17 days of 
parabiosis from 7 parabiotic pairs. (I and J) Number of HA-specific memory B 
cells in mediastinal lymph nodes (medLN) (I) and lungs (J) of parabiosis 
partners. (K and L) T-bet-ZsGreen expression in HA-specific memory B cells 
from mediastinal lymph nodes (K) and lungs (L) of T-bet-ZsGreen partner. HA-
specific memory B cells were not detected in the mediastinal lymph nodes or 
lung of the B6.SJL partner. Data displayed are from 8 pairs across three 
independent experiments for spleen and 4 pairs across two-independent 
experiments for mediastinal lymph nodes and lungs. HA-specific memory B cells 
were identified as live, singlet, DUMP-, B220+, CD19+, CD45.2+, IgD-, HA-




that are GL7+CD38- in the mediastinal lymph nodes and lungs of T-bet-ZsGreen 
mice 100 days post PR8 infection, and the percentage that are T-bet+ in each 
tissue (top). HA-specific memory B cells cells were identified as live, singlet, 
DUMP-, B220+, CD19+, IgD-, HA-AF647+, HA-BV421+ cells. DUMP gate includes 
CD4, CD8, Gr-1, and F4/80. Data in (D), (E), (F), (I), (J), and (M) show individual 
points with the mean ± SEM indicated. Statistical comparisons performed using 








2.3.5 Influence of B Cell Specific T-bet Expression on Antibody Isotype, Titers, 
and Specificity Following Influenza Infection 
 T-bet promotes class switching to the IgG2a/c isotype in mice and this 
isotype is important for multiple anti-viral and anti-bacterial responses, including 
influenza40, 55, 98, 99, 100, 101, 102, 103. As such, we compared the betapropiolactone 
(BPL) inactivated PR8 (PR8) and PR8 hemagglutinin (HA) specific IgG2c and 
IgG1 titers at various timepoints post PR8 influenza infection. We observed that 
titers peaked around day 21 and PR8-specific IgG2c and HA-specific IgG2c titers 
showed a greater increase than IgG1, evident by days 12 and 15 post infection, 
respectively (Figure 5A; 5B). This is consistent with prior studies104 and implies 
that T-bet likely plays a key role in antibody production following influenza 
infection.  
We wanted to explore the role of B cell specific T-bet expression on the 
PR8 influenza response. In order to investigate this, we infected B cell-specific T-
bet conditional knockout mice obtained by crossing Cd19tm1(cre)Cgn mice with 
Tbx21Flox/Flox mice (referred to as cKOs), heterozygous Cd19tm1(cre)Cgn cre controls 
(CD19 Cre), and wild type C57Bl/6 mice with PR8 influenza and interrogated the 
response in the three groups. All three groups showed similar weight loss 
kinetics, although the CD19 Cre controls had less overall weight loss and 
recovered lost weight faster (Figure 5C). The three groups had similar numbers 
of total HA-specific B cells at both day 15 and day 40 post infection (Figure 5D) 
along with an intact HA-specific GC response at day 15 (Figure 5E). As such, 




infection. Furthermore, an HA-specific B cell response can be initiated and 
maintained in the absence of T-bet expression in B cells.    
 We next explored the effect of B lineage T-bet deletion on antibody 
functionality as measured by hemagglutination inhibition (HAI) assay. At day 15 
post infection, the majority of mice in all three groups had HAI titers of at least 40, 
a level associated with protection in human studies105, 106 although a subset of 
cKO and wildtype mice had titers of 20 and below (Figure 5F). By day 40 post 
infection, HAI titers had decreased in all three groups, likely reflecting a decline in 
acute infection related IgM titers107 (Figure 5F). This decrease in titers was 
particularly notable in the cKO group, as by day 40 these mice had significantly 
lower HAI titers as compared to the wildtype or CD19-Cre controls and the 
majority of cKOs at day 40 had sub-protective levels of titers (Figure 5F). This 
implies that B cell specific T-bet expression may be required for sustained 
protective titers following influenza infection. 
 We proceeded to determine if the lower HAI titers in cKOs may be related 
to loss of a specific component of the antibody response. As expected, cKOs had 
significantly lower total BPL-inactivated PR8 IgG2c titers at both day 15 and 40 
post infection (Figure 5G). At day 15, cKOs had low IgG2c titers but these were 
nearly absent by day 40 post infection (Figure 5G), implying that T-bet-
independent mechanisms may initiate limited IgG2c switching during acute 
infection but B cell specific expression of T-bet is required for sustained IgG2c 
PR8-specific titers. We measured PR8 HA-specific titers as HA is a key antigenic 




infection, wildtype and CD19-Cre control mice had robust anti-PR8-HA IgG2c 
titers while these were largely absent in the cKO mice (Figure 5H), implying that 
B cell intrinsic T-bet is important for both an acute and sustained IgG2c response 
to PR8 HA. Furthermore, we measured IgG1 titers to both BPL-inactivated PR8 
and PR8 HA as this is a T-bet independent isotype. These titers were similar in 
all three groups at both days 15 and 40 post infection (Figure 5G; 5H) and did not 
undergo a compensatory increase in response to the lower IgG2c titers in cKO 
mice. While the majority of the influenza specific IgG2c response requires B cell 
specific T-bet expression; the IgG2c independent components of this response 
are preserved in the absence of T-bet expression in B cells.  
 Finally, we explored whether B cell specific T-bet expression is required 
for the influenza antibody response to defined specificities. Specifically, we 
explored the HA stalk specific antibody response as recent studies have shown a 
key role of HA-specific IgG2a/c antibodies for in vivo influenza protection, which 
are largely skewed toward stalk recognition108, 109. We measured IgG2c and IgG1 
titers to a chimeric construct comprised of the PR8-related H1 stalk and an 
unrelated H6 head110, 111. This allows us to selectively identify stalk specific 
antibodies as most PR8-generated HA head-binding antibodies are strain-
specific and do not recognize the unrelated H6 head. In wildtype mice, this stalk 
specific antibody response is dominated by IgG2c at both early and late 
timepoints and IgG1 stalk titers are negligible at both timepoints (Figure 5I). 
Furthermore, these IgG2c stalk-reactive titers are largely lost in cKOs with no 











Figure 5: Antibody Isotype, Titers, and Specificity Associated with B Cell 
Specific T-bet Expression 
 (A and B) Total betapropiolactone (BPL)-inactivated PR8-specific IgG1 and 
IgG2c (A) and PR8 hemagglutinin (HA)-specific IgG1 and IgG2c (B) in sera from 
infected T-bet-ZsGreen mice over time. (C). Weight loss and recovery from 
influenza infection in wild type C57Bl/6, CD19cre/WTT-betfl/fl, and CD19cre/WT mice 
compared to PBS-treated controls. (D) Number of HA-specific splenic B cells at 
day 15 and 40 post infection. (E) Number of HA-specific splenic germinal center 
B (GCB) cells at 15 days post infection. (F) Hemagglutination inhibition (HAI) 




PR8 (G), full-length PR8-HA (H), or chimeric construct comprised of H1 stalk and 
H6 head (I). Wild type C57Bl/6 were used for naïve controls in (F-I). Data are 
represented as mean ± SEM from 3 independent experiments with at least 3-5 
mice in each group. Statistical comparisons performed using two-sided t-test (G-
I) and Wilcoxon rank-sum test (F). *p<0.05, **p<0.01, ***p<0.001. Cells in (D, E) 
were identified as DUMP-, CD19+, B220+, CD138-, IgD-, HA-PE+, with the 
additional definition of germinal center B cells in (E) as PNA+CD95+. DUMP gate 






 There are multiple outstanding questions regarding the role, 
establishment, and characteristics of T-bet+ B cells in immune responses. In 
order to address this, we undertook a detailed study of T-bet expressing B cells 
following PR8 influenza infection. We found that T-bet expression can be used to 
separate PR8 HA-specific B cells into three subsets. These populations differ in 
multiple ways, including residency, effector function, and epitope specificity. At 
early timepoints, both T-bet+ and T-bet- HA-specific B cells display a GC 
phenotype and at later timepoints they assume a similar memory B cell fate. At 
acute timepoints post-infection, HA-specific T-bet-, T-betlow, and T-bethigh B cells 
can be observed in the responding secondary lymphoid tissues and the lungs. 
While all three populations persist at similar relative frequencies in the spleen for 
at least 100 days post infection, T-bethigh B cells largely disappear from the 
lymphatics and lungs. Using parabiosis, we have demonstrated that HA-specific 
T-bet- and T-betlow B cells recirculate between the spleens of the two partner 
mice, but T-bethigh B cells are splenic residents that remain restricted to the 
spleen of the previously infected partner. Furthermore, B cell specific T-bet 
expression is required for most HA-specific IgG2c and HA stalk specific titers, as 
mice lacking T-bet in B cells display a loss of these titers along with a failure to 
maintain protective neutralizing HAI titers at memory timepoints. Together, this 
shows that T-bet expression in B cells is an important determinant of populations 




We observed that HA-specific B cells appear in the spleen early following 
PR8 influenza infection and undergo expansion followed by contraction and 
maintenance regardless of T-bet expression. A fraction of these cells begin 
displaying a GC phenotype as early as day 7 post infection as evidenced by 
increased expression of GL7 and CD95 along with decreased CD38. This GC 
phenotype peaks at days 15 and 22, as a large majority of T-bet+ and T-bet- HA-
specific B cells express markers consistent with GC fate. Interestingly, T-bet 
expression may be related to the timing of entry and exit from the GC as HA-
specific T-bet+ B cells acquire and then lose a GC phenotype with faster kinetics 
than their T-bet- counterparts. The significance of possible accelerated GC 
kinetics in T-bet+ B cells remains unclear.  
At later timepoints, a large portion of T-bet+ and T-bet- HA-specific B cells 
express increased CD73. Higher levels of CD73 are suggestive of a GC origin for 
most T-bet+ and T-bet- HA-specific memory B cells91, 92. However, BrdU pulse 
labelling studies in an NP-CGG response have shown that a portion of memory B 
cells arising prior to day 5 and before the establishment of a robust GC response 
can also express elevated CD73. As such, expression of CD73 does not 
necessarily indicate a GC origin112. Nevertheless, the CD73+ B cell population is 
enriched for somatically mutated B cells as about 80% of CD73+ memory B cells 
are somatically mutated as compared to only 30% of the CD73- population92. A 
GC origin of T-bet+ memory B cells is consistent with prior findings showing that 
T-bet+ B cell formation requires CD40/CD40L interactions and is associated with 




 Outstanding questions regarding the role of HA-specific B cells in recall 
responses remain. Zuccarino-Catania et al. have demonstrated that memory B 
cells can be stratified into populations with different recall functions based on 
surface marker expression. In recall responses CD80+ PDL2+ memory B cells are 
biased towards rapid plasma cell differentiation and limited GC recruitment 
whereas CD80- PDL2- memory B cells participate in a robust GC response and 
fail to generate many early plasma cells36. A series of elegant experiments by 
Mesin et al. utilized a variety of approaches including clonal diversity and somatic 
hypermutation analysis, fate-mapping, and parabiosis to demonstrate that there 
is limited re-entry of germinal-center derived memory B cells into newly 
generated GCs following a CGG-Alum boost. Rather, memory B cells that 
participated in a GC following primary immunization are biased towards 
plasmablast differentiation in the recall response37.Taken together, the fact that 
the majority of HA-specific memory B cells in our studies expressed elevated 
levels of CD80 and PDL2 along with a GC history, it seems likely that these HA-
specific memory B cells would differentiate into antibody-secreting cells and fail 
to re-enter the GC during secondary exposure to influenza. Additional studies are 
required to confirm this hypothesis and to determine whether T-bet+ and T-bet- 
HA-specific B cells play differing roles in recall responses to influenza.  
 Our studies demonstrated unique anatomic compartmentalization 
corresponding to T-bet expression, with both T-bet+ and T-bet- HA-specific B 
cells present in the spleen, mediastinal LNs, lungs, and blood at early timepoints 




compartments for at least 100 days post infection, T-bet+ B cells displayed 
increasing splenic restriction with time. While the precise function and 
mechanism of this tissue compartmentalization remains unclear, it may be tied to 
differences in recirculation properties of T-bethigh, T-betlow, and T-bet- HA-specific 
B cells. In parabiotic studies, T-bet- and T-betlow B cells are observed to 
recirculate between the spleens of the two partner mice whereas T-bethigh B cells 
remain restricted to the spleen of the previously infected partner. We posit that 
the transient appearance of T-bethigh HA-specific B cells in the mediastinal LNs 
and lungs early after infection may reflect extra-splenic generation of these cells. 
Prior work from our lab has shown that intracellular nucleic acid sensing Toll-like 
receptor stimulation together with Th1 type cytokines such as IFNγ can induce T-
bet expression in B cells60. An inflammatory environment in the draining LNs or 
lungs shortly after infection may be sufficient to transiently drive T-bet expression 
in B cells at these sites. Consistent with this hypothesis, Barnett et al. observed a 
strong enrichment of T-bet+ memory B cells in the small intestinal mucosa 
following LCMV infection; a phenotype that was especially pronounced in the 
intraepithelial lymphocytes with more than 65% of these B cells expressing T-
bet51. The small intestinal mucosa, and in particular subepithelial CD11c+ 
dendritic cells, which reside in close proximity to intraepithelial lymphocytes, 
represents a major site of Clone 13 LCMV viral infection113, 114. Chronic viremia, 
immune activation, and inflammation may be sufficient to drive persistent T-bet 




which lead to persistent lymphoid tissue infections are associated with T-bethigh B 
cells residing in the infected LNs115, 116.  
 Integrin and chemokine receptor expression in T-bet+ B cells may be an 
additional important factor in the localization and recirculation properties of this 
population. We have observed that a substantial portion of T-bethigh B cells 
express the integrin CD11c. Work from the Wherry lab comparing gene 
expression between T-bet+ and T-bet- B cells showed that CXCR3, a gene 
involved in cell migration, was upregulated in T-bet+ B cells. They also confirmed 
this upregulation via flow cytometry51. In human peripheral blood, T-bet+ B cells 
express the integrin CD11c and the chemokine receptor CXCR3 along with low 
levels of CXCR4, CXCR5, and CCR7 which are chemokine receptors associated 
with homing to lymphoid organs49, 56, 71. Together, these surface receptors may 
act to block lymphatic entry of T-bethigh B cells and help establish their splenic 
residency. Intriguingly, we observed HA-specific T-bethigh B cells in the blood and 
their peak incidence corresponded to the loss of T-bethigh HA-specific B cells from 
the lungs and mediastinal LNs, consistent with their entry into the blood after 
activation or recent tissue exit. In accordance with this, an increase in T-bethigh B 
cells in human blood can be observed following influenza vaccination117.  
 In addition to their differences in localization and residency, T-bet+ and T-
bet- B cells differ in terms of function. B cell specific T-bet knockout mice fail to 
generate HA-specific IgG2c titers and show deficiencies in HA stalk specific 
antibody production and a failure to maintain protective HAI titers. We posit that 




heterologous strains of influenza. More specifically, T-bet+ B cells may be 
important in sustaining sterilizing immunity against reinfection and in generating 
broadly neutralizing HA stalk specific antibodies that could provide lasting 
protection against a wide variety of strains. At both baseline and 28 days post-
vaccination, higher absolute IgG stalk specific influenza titers in humans are 
associated with increasing age118. As T-bet+ ABCs accumulate with age, this 
increase in stalk specific antibodies could be dependent on T-bet+ B cells along 
with repeated exposure to divergent influenza strains. Additionally, T-bet+ B cells 
can be observed at increased frequencies following influenza vaccination in 
humans49, 117, 119. A major goal of current influenza research is the development 
of an HA stalk reactive vaccine which could provide protection against a broad 
range of divergent influenza strains and mitigate the need for annual 
revaccination and redesign. Given the likely importance of T-bet+ B cells in 
generating stalk specific antibodies and sustaining protective titers, developing 
vaccination strategies that promote the generation and maintenance of HA-
specific T-bet+ B cells is potentially a promising approach in the quest for a 





CHAPTER 3: T-bet+ Memory B Cells are a Stable Population That 
Contributes to Plasma Cell Pools 
3.1 Summary  
 In this chapter, we focus on the stability and fate of T-bet+ B cells. We 
show that T-bet expression in memory B cells is a durable state with T-bet+ and 
T-bet- memory B cells comprising stable, independent populations. We observed 
a trend of increasing CD138 expression with decreasing T-bet expression, 
suggesting that circulating Tbetlow B cells may be losing T-bet on their way to 
becoming plasma cells. In fact, a significant fraction of the plasma cell pool in 
both the spleen and bone marrow is derived from T-bet expressing B cells, and 
plasma cells can come from either T-bethigh or T-betlow precursors. Utilizing both 
fate mapper adoptive transfer and parabiosis followed by separation surgery 
techniques, we demonstrate that T-bethigh B cells give rise to T-betlow B cells but 
not vice versa. Nonetheless, T-betlow B cells persist for a minimum of three weeks 






The findings in the previous chapter resolve three memory B cell subsets 
with differing anatomic distributions and specificities, but the relationships 
between them, if any, is unclear.  Moreover, because B cell-specific T-bet 
expression is required for the bulk of HA-specific antibodies and sustained HAI 
titers, we reasoned that T-bet+ subsets likely contribute to plasma cell pools.   
Accordingly, we wanted to address whether there is frequent conversion between 
T-bet+ and T-bet- B cells, and to explore the relationship between spleen-resident 
T-bethigh B cells, recirculating T-betlow B cells, and plasma cells.  We were 
particularly interested in the ability of T-bet+ B cells to give rise to plasma cells 
and to determine whether T-betlow B cells are a transition stage between T-bet+ 
memory B cells and T-bet- plasma cells. 
Our prior results demonstrate that T-bethigh memory B cells are maintained 
long term at stable numbers in the spleen. In conjunction with the tissue 
residency of T-bethigh memory B cells, this suggests T-bet- and T-betlow B cells do 
not continuously give rise to T-bethigh B cells, as this would preclude T-bethigh B 
cells from being a uniquely splenic resident population. If T-betlow and T-bet- 
precursors generated T-bethigh B cells, then we would have expected to find T-
bethigh memory B cells in the spleens of both parabiotic partners. The 
maintenance of T-bethigh populations at steady numbers suggests it is unlikely 
that T-bethigh B cells simply lose T-bet expression as this would lead to 




B cells continually cycle with daughter cells leaving the T-bethigh pool to become 
T-bet-. 
In T cells, there is evidence that T-bet expression can be either a stable or 
dynamic state. In Th1 T cells, T-bet expression is required and acts to prevent 
the expression or function of transcription factors such as GATA-3 or RORγt 
which are associated with the differentiation of Th2 or Th17 T cells45, 82, 86, 120, 121, 
122. Studies in T-bet fate mapping mice have shown that T-bet expression in 
conventional CD4+ CD25- T cells is stable, as the majority of these fate mapped 
cells maintain T-bet expression123. 
On the other hand, regulatory T cells can express either T-bet or 
GATA3124, 125, 126, 127, but it remained unclear whether these were two separate 
subsets or if there was substantial interchange between these regulatory T cell 
populations. Using T-bet fate mapper mice, Yu et al. showed that T-bet 
expression in CD4+ CD25+ regulatory T cells is a dynamic state, as a large 
portion of these fate mapped cells rapidly lost T-bet expression. This was 
particularly pronounced in the LNs; over 60% of fate mapped CD4+ CD25+ 
regulatory T cells no longer expressed T-bet one week after tamoxifen 
treatment123. 
However, T-bet expression is not a simple on/off switch, as graded 
expression of T-bet has important implications on cell fate decisions. In CD8 T 
cells, the severity of inflammation and resultant IL-12 levels yield a gradient of T-




bet. The T-bet expression level influences cell fate decisions as low level T-bet 
expression promotes memory precursor effector cell development whereas high 
levels of T-bet drive the development of short lived effector cells128.  
Dynamic control of transcription factors also drives cell fate decisions in B 
cells. For example, IRF4 contributes to both GC B cell development and plasma 
cell differentiation, despite these processes being regulated by mutually 
antagonistic gene expression programs129, 130. IRF4 is thought to act in a “kinetic 
control” fashion, as transient low level expression is required for GC B cell 
development, whereas sustained high level expression leads to plasma cell 
generation129.    
Plasma cells and plasmablasts, collectively termed antibody secreting 
cells (ASCs), are terminally differentiated B cells that secrete antibody. The 
transition from B cell to antibody secreting cell involves extensive changes in 
gene expression, morphology, and cellular lifespan and entails the loss of B cell 
specific transcription factors and acquisition of plasma cell specific factors.  
These B cell and plasma cell specific transcription factors control gene 
expression networks that are mutually antagonistic resulting in a stable and 
irreversible B cell to plasma cell transition131, 132. 
T-bet expressing B cells may be important plasma cell precursors. 
Following Ehrlichia muris infection, CD11c+ T-bet expressing IgM plasmablasts 
are observed and likely give rise to long lasting bone marrow IgM plasma cells66, 
133, 134. Upon adoptive transfer followed by Ehrlichia muris reinfection , T-bet+ IgM 




required for the generation of long lived plasma cells and secondary ASCs 
following initial influenza infection or re-challenge with a heterologous strain54. 
In this chapter, we address the stability of T-bet+ B cells and examine their 
fate using genetic fate-mapping mice. We show that T-bet+ memory B cells are a 
stable population with limited interconversion into T-bet- B cell pools. However, 
we observe an increase in plasma cell characteristics, specifically CD138 
expression, that accompanies loss of T-bet expression, indicating that B cells 
downregulating T-bet may be on their way to becoming plasma cells. Indeed, 
both T-bethigh and T-betlow B cells give rise to plasma cells and T-bet expressing B 
cells can generate both B220+ and B220- plasma cells. Additionally, T-bethigh B 
cells give rise to T-betlow B cells. However, T-betlow B cells can be maintained 
independently from T-bethigh B cells for a minimum of three weeks.  
3.3 Results 
3.3.1 T-bet+ and Tbet- memory B cells are stable, independent populations 
 We wanted to determine whether T-bet+ and T-bet- memory B cells 
frequently interconvert or if they are maintained as separate B cell populations. In 
order to explore this question, we used a Tg (Tbx21-ZsGreen,-cre/ERT2)H3Jfz 
reporter/inducible cre transgenic mouse line123 bred to the 
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze conditional reporter allele background135. This 
yielded a combined T-bet reporter/fate mapper mouse (hereafter referred to as 
fate mapper). This mouse is T-bet sufficient and expresses the ZsGreen 




artificial chromosome. In these mice, treatment with tamoxifen during active T-bet 
transcription causes irreversible TD Tomato expression,  and active T-bet 
expression is associated with ZsGreen florescence123.  
Together, these two florescent markers delineate four cell populations; [1] 
cells that are not currently expressing T-bet and did not express T-bet at the time 
of tamoxifen administration (ZsGreen- TD Tomato-),  [2]  cells that expressed T-
bet at the time of tamoxifen administration and continue to express T-bet 
(ZsGreen+ TD Tomato+), [3] cells that expressed T-bet at the time of tamoxifen 
administration but no longer express T-bet (ZsGreen- TD Tomato+), and [4] cells 
that currently express T-bet but did not express T-bet at time of tamoxifen 
administration (ZsGreen+ TD Tomato-) (Figure 6A). By administering tamoxifen 
and performing longitudinal bleeds on the treated mice, we can track the 
persistence of T-bet expression with time by monitoring changes in the relative 
frequency of cells that retain T-bet expression (ZsGreen+ TD Tomato+) and cells 
that expressed T-bet during the treatment period but have subsequently lost 
expression (ZsGreen- TD Tomato+). We reasoned that if substantial conversion 
from the T-bet+ to the T-bet- B cell pool occurs, then there should be significant 
numbers of B cells that lose T-bet expression after being marked during 
tamoxifen treatment.  
We treated ≥ 20-week-old fate mapper mice with tamoxifen on days 0, 2, 
and 4 and performed a series of longitudinal bleeds. All mice displayed TD 
Tomato labelled CD3- CD19+ B cells by day 10 post tamoxifen treatment, and T-




population, often by a ratio of greater than 10:1 (Figure 6B). Importantly, the ratio 
of T-bet ZsGreen+ to T-bet ZsGreen- cells in the TD Tomato+ B cell population 
was maintained steadily with time in all mice (Figure 6B), suggesting that most B 
cells expressing T-bet at day 0 maintained T-bet expression for at least 40 days.  
We next wanted to explore T-bet persistence in memory B cells. In both 
humans and mice, most antigen-experienced B cells downregulate surface IgD 
expression upon transitioning towards memory B cell or plasma cell fate136, 137, 
138, 139, 140, 141. As such, we focused our analysis of T-bet persistence in tamoxifen 
treated fate mapper mice on IgD- B cells. Similar to total B cells, CD3- CD19+ IgD- 
B cells displayed evidence of TD Tomato fate mapping by day 10 post-tamoxifen 
treatment and the majority of these TD Tomato+ fate mapped IgD- B cells 
continued to express T-bet as evidenced by ZsGreen florescence (Figure 6C). 
Furthermore, there was no evidence of increasing T-bet loss with time in our 
sequential bleeds (Figure 6C), indicating that once T-bet expression is 
established it is stably maintained for a minimum of 40 days.  
While the majority of fate mapped IgD- B cells maintain T-bet expression, 
there are low numbers of fate mapped cells that have lost T-bet. Plasma cells are 
a terminally differentiated B cell fate and as such we wanted to determine 
whether cells that have lost T-bet expression remain memory B cells or are 
transitioning towards a plasma cell fate. In fate mapped IgD- B cells that lost T-
bet ZsGreen florescence, there is an increased level of CD138 expression as 
compared to fate mapped cells that maintained T-bet ZsGreen, indicating that 




as T-bet- memory B cells (Figure 6D).  This, along with sequencing data from our 
lab showing limited clonal overlap between T-bet+ and T-bet- HA-specific memory 
B cells in both mice and humans, suggests that T-bet expressing memory B cells 











T-bet Fate Mapping mice123 were treated with three doses of tamoxifen (Tam) to 
mark T-bet expressing cells with permanent, Rosa21-driven, tdTomato 
expression (A) and the status of T-bet expression of marked CD3- CD19+ (B) or 
CD3- CD19+ IgD- (C) B cells in the blood was tracked over 40 days. (D) 
Histogram of CD138 expression in TD Tomato+ (fate mapped) IgD- T-bet 
ZsGreen- (purple) or T-bet ZsGreen+ (blue) B cells a minimum of 40 days after 
tamoxifen treatment.  Four independent experiments were carried out with an 






3.3.2 T-bet expressing B cells give rise to plasma cells 
 In the previous section, we established that T-bet+ B cells are a stable, 
independent population and that the limited number of fate mapped cells that 
have lost T-bet expression have increased levels of CD138 and may be 
becoming plasma cells. In order to further address the correlation between loss 
of T-bet and gain in plasma cell characteristics, specifically CD138, we treated 
fate mapper mice with three doses of tamoxifen and waited for 40+ days. We 
then gated on live, CD19+, B220+, dump-, IgD-, IgM- switched splenocytes (Figure 
7A). Within this population, we analyzed CD138 expression in TD Tomato+ cells 
expressing varying levels of T-bet ZsGreen (Figure 7B). As we gated on cells 
positive for TD Tomato expression, we analyzed cell populations expressing T-
bet at the time of tamoxifen administration 40+ days prior. We observed a clear 
trend of increasing CD138 expression with decreasing levels of ZsGreen (Figure 
7B). Thus, loss of T-bet expression is likely associated with a gain in plasma cell 
character. 
As increasing CD138 correlates with loss of T-bet expression, we wanted 
to further explore the ability of T-bet+ B cells to give rise to plasma cells. Prior 
work has shown that T-bet+ B cells can give rise to various cell types upon 
transfer and re-challenge, including plasmablasts and memory B cells53,  but it 
remains unclear what happens to these T-bet expressing B cells in the absence 
of re-challenge. In order to address this question, we again utilized T-bet fate 




Fate mapper mice were treated with tamoxifen every other day for a total 
of three doses and maintained for a minimum of 40 days post-treatment. 
Following euthanasia, the spleen and bone marrow were analyzed for the 
presence of CD138+ plasma cells and the fraction of these cells expressing TD 
Tomato, indicating that they had been T-bet+ at the time of tamoxifen 
administration, was analyzed (Figure 8 A-D). We observed that on average 
greater than 16% of total splenic plasma cells were TD Tomato+, indicating that 
T-bet expressing B cells robustly give rise to CD138+ plasma cells (Figure 8C). 
TD Tomato+ CD138+ plasma cells were also present in the bone marrow, albeit 
at lower proportions, averaging around 7% of total bone marrow plasma cells 
(Figure 8D). 
 Since B220 expression can be used to stratify plasma cells into a primarily 
long lived B220- population and a largely short lived B220+ pool142, we decided to 
analyze the portion of plasma cells that were TD Tomato+ in each population 
(Figure 8B). While TD Tomato+ plasma cells were seen in both the B220+ and 
B220- plasma cell pools, a higher portion of B220+ plasma cells were TD 
Tomato+ as compared to B220- plasma cells in both the spleen and bone marrow 
(Figure 8C-D). This disparity was particularly evident in the bone marrow were 
there was a nearly 10-fold enrichment in the proportion of plasma cells that 
expressed TD Tomato in the B220+ versus B220- pools (Figure 8D). However, it 
remains to be seen whether fate mapped B cells give rise to higher proportions of 




 We directly assessed the turnover of TD Tomato+ plasma cells using BrdU 
labelling in the tamoxifen-treated fate mappers. As before, fate mapper mice 
were administered tamoxifen every other day for a total of three doses. Forty 
days after tamoxifen treatment, mice were placed on continuous BrdU treatment 
for either 13 or 20 days and the portion of B220+ and B220- plasma cells that 
were positive for BrdU was analyzed (Figure 8 E-F). In both TD Tomato+ and TD 
Tomato- plasma cells, a greater portion of B220+ as compared to B220- plasma 
cells had incorporated BrdU. In TD Tomato+ B220+ plasma cells, roughly 70% 
had incorporated BrdU whereas only around 20% of TD Tomato+ B220- plasma 
cells were positive for BrdU (Figure 8 E-F). This is consistent with prior results 
showing that B220+ plasma cells are a largely short lived population whereas 
B220- plasma cells represent a primarily long lived ASC pool142. 
As T-bethigh and T-betlow B cells have different tissue residency properties, 
we wanted to determine if T-betlow B cells were the plasma cell progenitor 
population or if T-bethigh B cells could give rise to plasma cells. This will help 
determine whether plasma cells arise from a continuously recirculating T-betlow 
population which could provide tissue surveillance for reinfection or if they are 
derived from a splenic resident T-bethigh population. In order to evaluate this, we 
utilized an adoptive transfer technique. We sorted splenic T-bethigh or T-betlow IgD- 
B cells following CD4, CD8, Ter119, F4/80, and Gr1 magnetic depletion from fate 
mapper mice treated 40+ days ago with tamoxifen. We then injected the sorted 
cells retro-orbitally into separate B6.SJL congenic donors. We waited a minimum 




Tomato+, CD45.2+ adoptively transferred CD19+ B cells and CD138+ plasma cells 
derived from T-bethigh or T-betlow transferred memory B cells in order to determine 
what populations give rise to plasma cells (Figure 9A-C). As TD Tomato+ B cells 
were expressing T-bet at the time of tamoxifen administration 40+ days prior to 
sorting and adoptive transfer, we used TD Tomato positivity as a surrogate 
marker for memory B cells.  
Despite the low number of recovered cells, we observed donor derived 
CD138+ plasma cells in mice receiving either T-bethigh of T-betlow B cells (Figure 
9D). Thus, both T-bethigh and T-betlow B cells can serve as progenitors for plasma 
cells with increasing plasma cell characteristics acquired with loss of T-bet in 






Figure 7: Increasing CD138 with loss of T-bet ZsGreen in fate mapped B 
cells and plasma cells 
(A) Pregating strategy for the analysis of CD138 expression in class switched B 
cells in tamoxifen treated fate mapper mice. (B) Overlay flow plots showing 
CD138 expression in TD Tomato+ fate mapped T-bethigh (purple), T-betlow (blue), 
and T-bet- (orange) B cells. DUMP gate includes CD4, CD8, Gr-1, and F4/80. 
Data displayed are representative of three independent experiments with a 








Figure 8: T-bet+ B cells give rise to B220+ and B220- plasma cells 
 (A) Pregating strategy for the identification of plasma cells (PCs) in tamoxifen 
treated fate mapper mice. (B) Stratification of plasma cell populations by B220 
staining and identification of the TD Tomato+ fate mapped fraction. (C and D) 
Proportions of plasma cell populations in the spleen (C) and bone marrow (D) 
that are TD Tomato+ (fate mapped). (E) Representative histogram showing BrdU 




that are BrdU+ after various periods of BrdU administration. DUMP gate includes 
CD4, CD8, Gr-1, and F4/80. Data in (C) and (D) show individual points with the 
mean ± SD indicated. Data in (A), (B), (C), and (D) are representative of or 
compiled from a minimum of three independent experiments with a minimum of 
three mice each. Data in (E) and (F) are representative of or compiled from two 
independent experiments with two mice each (Day 13) or one experiment with 3 










(A) Experimental design for fate mapper T-bethigh and T-betlow adoptive transfer 
studies. (B) Sorting strategy for T-bethigh and T-betlow B cells from tamoxifen 
treated fate mapper donor mice. (C) Gating scheme for the identification of TD 
Tomato+ fate mapped donor derived CD45.2+ B cells and plasma cells in B6.SJL 
adoptive transfer recipients. (D) Overlay flow plots showing CD138 and T-bet 
ZsGreen expression in TD Tomato+ fate mapped donor derived CD45.2+ B cells 
and plasma cells recovered from B6.SJL recipients receiving either T-bethigh (red) 
or T-betlow (blue) sorted donor cells. DUMP gate includes CD4, CD8, Gr-1, and 







3.3.3 T-bethigh memory B cells give rise to T-betlow memory B cells that persist for 
a minimum of three weeks in the absence of a T-bethigh progenitor pool 
 Since both T-bethigh and T-betlow B cells give rise to plasma cells, we 
wanted to further explore the relationship between these B cell populations. In 
order to evaluate this, we once again utilized an adoptive transfer approach. In 
brief, we treated fate mapper mice with three doses of tamoxifen and waited 40+ 
days after which we sorted splenic T-bethigh or T-betlow IgD- B cells following CD4, 
CD8, Ter119, F4/80, and Gr1 magnetic depletion (Figure 9A-B). We then injected 
these cells retro-orbitally into separate B6.SJL congenic donors and waited for a 
minimum of three weeks prior to analyzing transferred live, dump-, TD Tomato+, 
CD45.2+ memory B cells in the spleen of the recipient mice (Figure 10A). 
We observed that adoptively transferred TD Tomato+ T-bethigh B cells gave 
rise to T-betlow B cells whereas TD Tomato+ T-betlow B cells failed to become T-
bethigh B cells (Figure 10B). This indicates that, unlike the total T-bet+ and T-bet- 
memory B cell pools which are maintained as separate populations with limited 
interconversion, there is substantial transit from the spleen resident T-bethigh into 
the circulating T-betlow memory B cell pool. This does not occur in the reverse 
direction, as T-betlow memory B cells do not give rise to T-bethigh memory B cells. 
Based on our data showing that T-bethigh memory B cells can give rise to 
T-betlow B cells, we wanted to address whether T-betlow B cells can be maintained 
as a stable population or if they represent a transient population continuously 
seeded from T-bethigh B cells. Utilizing our adoptive transfer results, we observed 




(Figure 10B). This indicates that T-betlow memory B cells can persist for a 
minimum of three weeks in the absence of a T-bethigh feeder pool and do not 
require T-bethigh B cells for their continued maintenance. Future studies will be 
required to evaluate the sustained presence of T-betlow memory B cells in the 
absence of T-bethigh memory B cells at later timepoints. 
As another means of assessing the persistence of T-betlow memory B cells 
in the absence of a T-bethigh population, we separated parabiosied partners and 
tracked circulating memory B cell subsets in the uninfected B6.SJL partner 
(Figure 11A). In our earlier work, we demonstrated that by 17 days post-
parabiosis the mice had established a shared circulatory system and that HA-
specific T-bet- and T-betlow B cells recirculated and could be found in the spleens 
of both partner mice (Figure 4B-G). Importantly, T-bethigh HA-specific B cells were 
restricted to the spleen of the previously infected partner and were absent from 
the congenic B6.SJL partner (Figure 4D-G). While the previously infected partner 
has all three HA-specific memory B cell subsets, the B6.SJL congenic partner 
lacks the T-bethigh HA-specific B cell pool, allowing us to determine whether 
maintenance of the T-betlow memory B cell pool requires a T-bethigh progenitor 
pool. If the T-betlow B cell pool was short-lived and required continuous seeding 
from T-bethigh progenitors, T-betlow B cells would not be sustained once isolated 
from T-bethigh B cells. Therefore, we euthanized the mice after being separated 
for a minimum of three weeks and analyzed the HA-specific memory B cell pools 




As expected, IgD- HA-specific B cells were observed in both partner mice 
and the vast majority of these HA-specific B cells were CD45.2+ (Figure 11B), 
indicative of their origin in the previously infected T-bet ZsGreen partner. The 
HA-specific T-bethigh population was only observed in the previously infected 
ZsGreen partner and was absent in the uninfected B6.SJL partner while HA-
specific T-bet- B cells were observed in both partner mice (Figure 11C-E). 
Importantly, we were able to detect an appreciable HA-specific T-betlow 
population in both the B6.SJL and T-bet ZsGreen partners (Figure 11C-E). This 
indicates that T-betlow B cells are maintained independently from T-bethigh B cells 
for a minimum of three weeks, as HA-specific T-bethigh B cells were absent from 
the B6.SJL partner and unable to contribute to the maintenance of the T-betlow B 
cell pool. It is possible that the frequency of HA-specific T-betlow B cells may be 
decreasing in the absence of a T-bethigh seeder population, indicating that over a 
longer timeframe this T-betlow population may be lost in the absence of a T-bethigh 
progenitor pool. These data together with our adoptive transfer results 
demonstrates that while T-betlow memory B cells can be generated from T-bethigh 
precursors, T-betlow memory B cells do not require T-bethigh progenitors for their 
continued maintenance for a minimum of three weeks. Thus, T-betlow B cells may 
represent a self-renewing population which can be maintained in the absence of 









Figure 10: T-bethigh B cells give rise to T-betlow B cells that persist in the 
absence of a T-bethigh feeder pool for a minimum of three weeks 
(A) Gating scheme for the identification of TD Tomato+ fate mapped donor 
derived CD45.2+ B cells in B6.SJL adoptive transfer recipients. (B) Overlay flow 
plots showing TD Tomato+ fate mapped donor derived CD45.2+ B cells recovered 
from B6.SJL recipients receiving either T-bethigh (red) or T-betlow (blue) sorted 
donor cells. DUMP gate includes CD4, CD8, Gr-1, and F4/80. Data displayed are 














Figure 11: Independent maintenance of T-betlow memory B cells as 
demonstrated by parabiont separation  
(A) Experimental design for parabiosis followed by separation surgery studies. 
(B) Gating scheme for the identification of T-bet-ZsGreen derived CD45.2+ HA+ B 
cells in T-bet ZsGreen (top) and B6.SJL (bottom) separated parabionts. (C) 
Subsetting of HA+ CD45.2+ B cells into T-bet-, T-betlow, and T-bethigh populations 
via flow cytometry in T-bet ZsGreen (left) and B6.SJL (right) separated 




cells (MBCs) per 106 CD45.2+ B cells in T-bet-ZsGreen (left) and B6.SJL (right) 
separated parabionts. (E) Numbers of T-bet-, T-betlow, and T-bethigh HA+ splenic 
memory B cells in T-bet-ZsGreen (left) and B6.SJL (right) separated parabionts. 
DUMP gate includes CD4, CD8, Gr-1, and F4/80. Data in (D) and (E) show 
individual points with the mean ± SD indicated. Data displayed are representative 





 These studies investigate the stability and fate of T-bet expressing B cells. 
Using T-bet fate mapper mice, we demonstrated that T-bet+ B cells are a stable 
population with limited conversion into the T-bet- B cell pool. In fate mapped 
memory B cells, increasing CD138 expression corresponds with lower T-bet 
levels, indicating that a decrease in T-bet expression in B cells may be 
associated with a gain in plasma cell characteristics. Indeed, a substantial portion 
of both splenic and bone marrow plasma cells, especially in the B220+ plasma 
cell population, are derived from T-bet expressing B cells despite only a brief 
window of tamoxifen treatment, and both T-bethigh and T-betlow B cells can give 
rise to plasma cells. Additionally, T-bethigh B cells give rise to T-betlow B cells, but 
T-betlow B cells do not upregulate T-bet in order to enter the T-bethigh B cell pool. 
Nevertheless, T-betlow memory B cells can be maintained in the absence of a T-
bethigh B cell pool for a minimum of three weeks, indicating that T-betlow B cells 
may represent a self-renewing population that can be maintained in the absence 
of T-bethigh B cells. Taken together, these findings demonstrate that T-bet+ 
memory B cells give rise to plasma cells, and that T-bethigh B cells can contribute 
to both the T-betlow B cell pool and plasma cell populations. 
 While our prior results demonstrated that both T-bet+ and T-bet- memory B 
cells are generated and sustained long term in the spleen following PR8 
influenza infection and that T-bet+ B cells are important for IgG2c and stalk-
specific antibody responses as well as sustained protective HAI titers, it 




bet+ and T-bet- B cell pools. Our fate mapper results demonstrate the absence of 
sustained entry of T-bet+ B cells into the T-bet- B cell pool, indicating that T-bet+ 
and T-bet- B cells are maintained as separate populations.  
 There are remaining questions regarding the role of T-bet+ and T-bet- B 
cells, particularly in recall responses to mutating pathogens as seen with immune 
imprinting or original antigenic sin (OAS). Infective pathogens, particularly rapidly 
mutating viruses, can undergo antigenic variation wherein mutations lead to 
alterations in surface antigens, subverting high affinity recognition by previously 
generated antibodies. In the case of influenza, antigenic drift can lead to frequent 
changes in antigenically important sites which can drastically impair antibody 
recognition and immune protection143. During subsequent exposure to the 
antigenically drifted pathogen, the antibody response is biased towards the 
previously encountered strain which impairs the response to the current infecting 
strain144. The concept of OAS has striking similarities to carrier-mediated hapten 
suppression wherein prior exposure to a carrier protein leads to suppression of 
the hapten antibody response during subsequent hapten-carrier immunization145. 
Additional work has shown that carrier-mediated hapten suppression has a 
particularly strong effect on blocking hapten specific IgG2a/c responses during 
the secondary hapten-carrier immunization146. As class switching to the IgG2a/c 
isotype is strongly associated with T-bet expression40, 42, 100, T-bet+ B cells may 
play an important role in carrier-mediated hapten suppression and OAS. Indeed, 
in carrier-mediated hapten suppression, the Th1 type response is largely 




environment60, lack of a Th1 type response likely impairs the T-bet+ B cell 
response. OAS can be subverted in a murine heterologous influenza challenge 
model if adjuvants that induce a Th1 type response are added to the vaccination 
regimen148, implying that the lack of Th1 type cytokines and T-bet+ B cells may 
play a key role in OAS and carrier-mediated hapten suppression. As such, 
properly regulating the recruitment of T-bet+ memory B cells during vaccination 
and re-challenge may be an important way to avoid OAS and provide optimal 
sustained protection against rapidly mutating pathogens. Specifically, inducing a 
Th1 type environment may help recruit memory T-bet+ B cells or generate new T-
bet+ B cells in the recall response and allow subversion of OAS.  
We have shown that loss of T-bet correlates with increasing CD138 levels 
and that T-bet+ B cells are able to generate plasma cells. This prompts questions 
regarding the potential role of T-bet expression in controlling antibody-secreting 
cell differentiation. Stone et al. have demonstrated that suppression of IFNγ 
mediated inflammatory effects on B cells via T-bet expression is likely important 
in promoting plasma cell differentiation, in particular in recall responses54. 
Additionally, B cell intrinsic T-bet is required for IgG2a/c plasma cell 
differentiation, likely via STAT1100. As rising levels of CD138 are observed with 
decreasing T-bet, it is possible that CD138 itself may function to help assure 
plasma cell differentiation and survival upon the progressive loss of T-bet. 
Notably, Blimp1 can antagonize T-bet expression149 and plasma cells with higher 




assessed100, implying a possible link between increasing plasma cell 
differentiation and decreasing T-bet levels. CD138 likely acts in a cell intrinsic 
manner to promote plasma cell accumulation and survival in vivo. Cell surface 
CD138 expression increases heparan sulfate levels on plasma cells and this 
leads to increased binding of pro-survival cytokines such as IL-6 and APRIL and 
increased plasma cell survival150. T-bet mediated suppression of IFNγ induced 
inflammation may no longer be required for survival and plasma cell 
differentiation upon increased expression of CD138.  
 While both T-bethigh and T-betlow B cells give rise to plasma cells, there are 
important differences between these cell populations warranting further 
investigation of the relationship between these B cell pools. Our prior results 
demonstrated that T-bethigh and T-betlow B cells differ in their recirculation 
capacity, as T-bethigh HA-specific memory B cells are splenic resident whereas T-
betlow memory B cells recirculate between parabiotic partners. While it is tempting 
to speculate that circulating T-betlow B cells are a transient population derived 
from stationary, self-renewing T-bethigh B cells on their way to becoming T-bet- 
plasma cells, the situation is likely more complex. T-betlow B cells can be 
maintained in the absence of a T-bethigh population for a minimum of three 
weeks. Thus, a portion of T-betlow B cells are a stable and persistent population 
that may have separate maintenance and induction requirements from the T-
bethigh subset. These two possibilities are not mutually exclusive as the T-betlow B 




 It will be of interest to determine the role of T-bethigh and T-betlow B cells in 
a recall response, as both populations give rise to plasma cells. Future studies 
exploring whether T-bethigh and T-betlow B cells have different requirements for 
their induction and maintenance are warranted. One possibility is that T-bethigh B 
cells may require a splenic niche for their generation whereas T-betlow B cells 
may be able to be generated at alternative sites such as reactive LNs. 
Splenectomy followed by infection and subsequent evaluation of B cell 
populations at early time points may help in resolving this question. 
  As T-bethigh B cells are maintained long term at stable numbers while also 
giving rise to T-betlow B cells and plasma cells, we posit that T-bethigh memory B 
cells may have a stem like nature. Indeed, Kenderes et al. have demonstrated 
that T-bet+ IgM memory B cells generated following Ehrlichia muris infection can 
both self-renew and generate multiple lineages of effector B cells following re-
challenge, demonstrating their stem-like nature53. Our studies extend these 
findings by establishing the presence of both T-bethigh and T-betlow memory B 
cells and showing that T-bet+ B cells continue to generate plasma cells in the 
absence of re-challenge. Future studies such as rapamycin treatment or 
sublethal irradiation to further explore the stem-like nature of T-bethigh B cells are 
of interest. 





CHAPTER 4: Conclusions, Implications, and Future Directions 
We have undertaken a detailed investigation of T-bet+ B cells including 
their emergence, maintenance, and role in a murine influenza infection model, 
their stability, and their ability to give rise to antibody secreting cells. As T-bet 
expressing B cells are important in the control of a variety of infectious diseases 
and contribute to autoimmunity in both mice and humans, a better understanding 
of the requirements for the emergence and maintenance of this population along 
with their terminal differentiation fate could help inform more effective 
prophylactic vaccines and treatments for autoimmune pathologies.  
In chapter two, we have shown that following PR8 influenza infection in 
mice, T-bet+ HA-specific B cells emerge in the spleen, lungs, and draining 
mediastinal LNs at acute timepoints. At memory timepoints, T-bet+ HA-specific B 
cells become progressively restricted to the spleen, despite the continued 
presence of T-bet- HA-specific B cells at other anatomical sites. Both T-bet+ and 
T-bet- HA-specific B cells first display a GC phenotype before transitioning to a 
CD73+ CD80+ PD-L2+ memory phenotype. T-bet+ B cells can be further subset 
into T-bethigh and T-betlow B cells, with T-bethigh HA-specific B cells being a spleen 
resident population as evidenced by parabiosis studies. Furthermore, T-bet 
expression in B cells is required for HA-specific IgG2c titers and sustained 
protective HAI titers. Additionally, stalk specific influenza antibodies are largely 
ablated in the absence of T-bet expressing B cells (Figure 12).  
In chapter 3, we utilized fate mappers to demonstrate that most T-bet 




population from T-bet- B cells. We also showed that T-bet+ B cells differentiate 
into plasma cells: downregulation of T-bet is associated with a gain in plasma cell 
characteristics, as evidenced by increasing CD138 expression, and a portion of 
plasma cells in both the bone marrow and spleen are derived from T-bet 
expressing B cells. Notably, T-bet+ B cells are especially apt at producing B220+ 
plasma cells. We further demonstrated that T-bethigh B cells can give rise to T-
betlow B cells as well as plasma cells. However, T-betlow B cells can still be 
maintained independently of T-bethigh B cells for a minimum of three weeks 





Figure 12: Residency, function, and fate of T-bet expressing B cells 	
Following PR8 influenza infection, T-bet-, T-betlow, and T-bethigh memory B cells 
are established and maintained long term. While T-bet- and T-betlow memory B 
cells recirculate, T-bethigh memory B cells are restricted to the spleen and are 
resident. T-bet+ B cells are required to establish hemagglutinin stalk specific 
antibody titers. While T-bethigh B cells can give rise to T-betlow B cells, T-betlow B 
cells fail to become T-bethigh. Furthermore, the T-bet+ B cell pool is maintained as 
a stable, separate population from the T-bet- B cell population. Both T-bethigh and 
T-betlow B cells can give rise to B220+ and B220- plasma cells with increasing 




These studies suggest that the T-bet expressing B cell population 
constitutively generates plasma cells at a basal rate. While this may reflect 
antigenic stimulation from self-antigens or antigens endogenous to our colony, 
the magnitude of plasma cell differentiation observed raises alternative 
possibilities. We postulate that there may be continuous differentiation of T-bet+ 
B cells into plasma cells, potentially in an antigen-independent manner, 
functioning to support maintenance of neutralizing antibody titers at levels 
sufficient to provide sterilizing immunity.  
While the classic view of immune memory emphasizes the effectiveness 
of antigen specific memory lymphocytes in mounting a rapid secondary 
response, protective immune memory relies heavily on maintenance of protective 
antibody titers. In fact, vaccination is often aimed at eliciting sufficient protective 
titers to maintain sterilizing immunity long term, even in the absence of persistent 
antigen151. This is particularly important in providing protection against toxins, 
where pathology may be too rapid to allow the generation of a secondary 
response to be effective152. In clinical veterinary medicine, the importance of 
protective antibody titers can be seen in the management of newborn animals. 
Assuring that newborn cattle rapidly get appropriate, high quality colostrum in 
order to allow passive transfer of maternal antibodies is considered the most 
important management factor in assuring calf survival153. Up to 31% of calf 
mortality events in the first 21 days of life can be attributed to failure of passive 
transfer154. Furthermore, passive immunization in the form of antibody transfer 




immunization and neutralizing antibodies can be seen in the treatment and 
prevention of diphtheria, where Behring’s discovery of the use of immune serum 
massively reduced morbidity and mortality. In fact, it was hailed by the Lancet as 
the “most important advance of the century in the medical treatment of acute 
infective disease”155. In Germany alone, diphtheria treatment via passive 
immunization is credited with having saved as many as 45,000 lives per year156.  
Appropriate maintenance of protective titers is essential for effective 
immune protection and optimal health. While these lasting titers have often been 
accredited to long-lived bone marrow plasma cells, recent work has shown that 
newly formed, rapidly turning over plasma cells likely play a major role in long 
term antibody titer maintenance142. These plasma cell subsets can be 
distinguished on the basis of B220 expression as BrdU labelling studies have 
demonstrated that B220- plasma cells are primarily long lived whereas B220+ 
plasma cells are largely short lived142. While our studies show that T-bet 
expressing B cells can generate both B220+ and B220- plasma cells, a higher 
portion of B220+ plasma cells are derived from T-bet expressing B cells as 
compared to B220- plasma cells. Thus, we posit that T-bet+ memory B cells play 
a key role in the maintenance of lasting protective titers by continuously 
generating antibody secreting plasma cells.  
Multiple lines of research support the importance of T-bet+ B cells in giving 
rise to plasma cells that maintain antibody titers. Our work showed that mice 
lacking B cell specific T-bet expression failed to sustain protective HAI titers long 




T-bet+ IgM memory B cells generate ASCs following Ehrlichia muris infection53. 
Influenza vaccine-generated CD21low B cells, which express increased levels of 
T-bet mRNA and protein, are similarly poised for plasma cell differentiation as 
they have elevated expression of plasma cell associated genes such as BLIMP-
149. Further, T-bet+ B cells isolated from lupus patient blood are able to rapidly 
differentiate into plasma cells upon TLR7 and IL-21 stimulation in the absence of 
cell division67, and lupus prone mice lacking T-bet+ B cells demonstrate reduced 
autoantibody titers and kidney pathology, leading to improved survival57. 
Interestingly, the memory marker profile observed on our HA-specific T-bet+ B 
cells is also consistent with plasma cell differentiation as opposed to GC entry 
following re-stimulation36, 37. A recent study by Stone et al. further demonstrates 
the role played by T-bet-expressing B cells in plasma cell differentiation during 
the influenza recall response to heterologous challenge, as inducible deletion of 
T-bet in memory B cells causes an up to 10-fold reduction in levels of induced 
total and IgG2c antigen-specific plasma cells. Interestingly, T-bet is not required 
for the survival of T-bet+ memory B cells, but rather for plasma cell differentiation, 
as memory B cell numbers are not impacted by inducible T-bet deletion. T-bet 
mediated repression of an IFNγ dependent inflammatory gene program may be 
important in promoting plasma cell differentiation54. 
Assuming that T-bet+ B cells are continuously generating plasma cells, 
regulation of this process is necessary to assure that appropriate numbers of 




this differentiation is regulated by circulating antibody levels. T-bet+ B cells may 
detect a decrease in free circulating antibody, as could happen after re-exposure 
to a pathogen due to formation of antigen-antibody complexes. This could induce 
increased numbers of T-bet+ B cells to undergo plasma cell differentiation. In 
support of such an idea, Kenderes et al. observed that T-bet+ IgM memory B 
cells failed to differentiate into plasma cells in chronically infected mice that have 
high titers of protective antibodies but most of these cells became plasma cells in 
newly infected mice lacking pre-existing titers53. Multiple myeloma patients have 
reduced levels of normal polyclonal serum immunoglobulins, likely due to a B cell 
extrinsic mechanism which prevents B cells from differentiating into plasma 
cells157; such a mechanism could be dependent on the high levels of monoclonal 
antibodies arising from malignant plasma cells. Studies by Pape et al. further 
support such a mechanism, as immune serum transfer decreased memory B cell 
to plasma cell differentiation158. If such a mechanism is in play, we would expect 
decreased levels of plasma cell generation from T-bet expressing B cells in the 
presence of increased antibody levels. Conversely, plasma cell genesis from T-
bet+ B cells would likely be increased in mice with lower total antibody titers. 
While the mechanism is unclear, increased Fc receptor binding is a possible 
candidate that may suppress this differentiation33, 159. Future studies to compare 
the expression levels and types of Fc receptors on T-bet+ and T-bet- memory B 
cells will be necessary to investigate this possibility. 
Conversely, T-bet+ B cells may be induced to differentiate into plasma 




memory B cells that proliferate and differentiate into plasma cells following 
activation with polyclonal stimuli such as CpG DNA or bystander T cell help160. 
ABCs, a large fraction of which are T-bet+, show robust responses to innate 
stimuli: as compared to follicular B cells, ABCs fail to respond to BCR 
crosslinking and/or anti-CD40, but robustly proliferate in response to TLR9 
stimulation as provided by CpG41. 
An alternative possibility is that T-bet+ B cells may express broadly 
reactive BCRs allowing them to be stimulated and differentiate into plasma cells 
in response to a range of conserved antigenic determinants. Such ideas are not 
unprecedented, as MZ B cells often express polyreactive BCRs that can bind to a 
range of microbial molecular patterns. In addition, MZ B cells have high levels of 
TLR expression and dual stimulation of the BCR and TLR can result in rapid 
differentiation of this subset into antibody secreting plasma cells161. A similar 
situation may be occurring with T-bet+ B cells, and indeed these B cells are 
responsible for the antibody response to the conserved stalk epitopes in 
influenza infection. It would be interesting to see if T-bet+ B cells are responsible 
for the antibody response to other conserved antigenic determinants.  
Importantly, these possibilities imply that T-bet+ B cell memory may have 
innate-like characteristics, and this may help to explain the purpose for splenic 
residency of T-bethigh memory B cells. Under this concept, T-bet+ B cells localized 
to the spleen would function to rapidly detect circulating factors associated with 
infection in order to quickly increase plasma cell genesis and protective antibody 




T cells, where parabiosis studies demonstrate that both CD4 and CD8 T cells 
establish tissue resident memory (TRM) populations in various organs and barrier 
sites26, 162, 163, 164. These TRM populations provide important and rapid protection 
against a wide variety of local reinfections through various means including direct 
effector functions and recruitment and activation of other immune cells30. 
Hpwever, TRM can also be maladaptive and contribute to allergic or autoimmune 
pathology165. 
In terms of B cells, tissue resident memory is less appreciated. B cells 
give rise to plasma cells, which secrete antibodies that freely recirculate, and as 
such the importance of residency is less clear. Studies from Young et al. 
comparing lymphocytes in the blood and lymph of sheep demonstrated that the 
majority of non-recirculating peripheral blood lymphocytes were B cells. These 
non-recirculating B cells lacked surface expression of CD21 and thus may 
correspond to the CD21- CD23- T-bet+ ABC population observed in mice and 
humans166. Furthermore, it may be important for B cells to persist at sites of 
infection to allow rapid stimulation and differentiation into antibody secreting 
plasma cells upon local reinfection. In fact, research from the Randall lab has 
utilized parabiotic studies to demonstrate that lung resident memory B cells are 
established following intranasal influenza infection and require local antigen 
encounter for their generation. Upon local intranasal re-challenge, these lung 
resident memory B cells rapidly give rise to antibody secreting plasmablasts 





While tissue residency in both B and T cells may be important in providing 
surveillance and protection against local reinfection, this explanation seems less 
likely for spleen resident HA-specific T-bethigh B cells. Influenza is a respiratory 
infection and does not replicate in the spleen, making this an unlikely site for 
reinfection167. However, the idea of resident memory cells in secondary lymphoid 
organs is not unprecedented: resident CD4 T cells can be found in the cervical 
and mesenteric LNs and peyers patches168, and parabiosis studies identify 
antigen-specific resident CD8 T in the draining mediastinal LN more than a 
month after influenza infection. This is likely related to the persistence of 
processed viral antigens in the draining nodes, since CFSE labelled antigen-
specific CD8 T cells show increased proliferation in the mediastinal LNs following 
transfer into previously infected mice as much as 60 days after infection169. 
Antigen persistence in the draining LNs may also explain the maintenance of 
mediastinal LN-resident HA-specific T-bet- B cells that we observed in parabiosis 
studies, as these displayed a GC phenotype as late as 100 days post influenza 
infection.  
While it is possible that antigen persists long term in the spleen following 
influenza infection, this is unlikely to explain the splenic residency of T-bethigh 
memory B cells for several reasons. First, only T-bethigh memory B cells were 
splenic resident and T-bet- and T-betlow B cells were able to freely recirculate 
between parabiotic partners. Additionally, there was no noticeable expansion of 
HA-specific cells in the CD45.1 B cell fraction in the spleen of the previously 




splenic T-bet+ B cells’ loss of GC phenotype and transition to memory phenotype 
by day 40 post infection suggests antigen is largely cleared. In support of 
antigen-independent maintenance, parabiosis studies show that lymphocytes can 
be resident in secondary lymphoid organs in the absence of persistent antigen: 
resident LCMV-specific memory CD8 T cells can be found in the spleen and LNs 
of LCMV Armstrong infected mice well after viral clearance, and CD69, which is 
associated with tissue residency, is not upregulated until after viral clearance170.  
Furthermore, the localization of resident memory lymphocytes within 
secondary lymphoid organs is not random, and this may have important 
functional implications for splenic resident T-bethigh memory B cells. Using a 
combination of parabiosis and immunofluorescence microscopy, Schenkel et al. 
showed that antigen specific CD8 memory T cells in the LNs of the previously 
LCMV infected partner were largely localized to the LN sinus, whereas in the 
uninfected partner these cells were primarily found in the T cell zone. Likewise, 
these antigen specific CD8 T cells preferentially reside in the splenic MZ at the 
expense of the white pulp in the previously infected parabiont170. Importantly, the 
splenic MZ and LN subcapsular sinus are prime sites for a wide range of initial 
microbial entry and antigen capture and presentation171, 172, 173, 174, 175. In 
particular, the splenic MZ is specialized for blood borne antigen surveillance, with 
a unique microarchitecture resulting in the slowing of blood flow to allow efficient 
capture of antigens from the blood stream176. MZ macrophage antigen capture is 
important for the proper control of certain infections, as mice lacking proper 




pathogens such as Listeria monocytogenes or Streptococcus pneumoniae and 
are more susceptible to death174, 177. MZ B cells are a largely resident population, 
as demonstrated by their limited migration in parabiosis studies and numerical 
persistence in the non-irradiated section of the partially irradiated spleen in 
rats178, 179. This MZ retention is likely dependent on the interaction between 
Sphingosine 1-phosphate receptor 1 (SIP1) and CXCL13, since MZ B cells are 
displaced from the MZ into the splenic follicles in S1P1 deficient mice. In 
S1P1/CXCL13 double deficient mice, normal MZ B cell localization is restored, 
indicating that S1P1 functions to block CXCL13 mediated recruitment of MZ B 
cells to the splenic follicles180. 
In light of the importance of the MZ in antigen surveillance, it is tempting to 
speculate that the splenic resident T-bethigh population observed after influenza 
infection may be localized to the MZ. In such a case, these cells would be 
uniquely positioned to support broad immune surveillance and rapidly detect 
invading pathogens. Indeed, previous studies have shown that memory B cells 
can be found in the MZ and perifollicular regions of the spleen181, 182, and much 
of this localization is dependent on CCR6. In mice lacking CCR6, the frequency 
of memory B cells in the perifollicular region is massively decreased, while their 
frequency in follicular regions is increased more than 6-fold. However, the 
frequency of memory B cells in the MZ is not significantly changed in CCR6 
knockout mice. CCR6 may be important in recall responses as bone marrow and 
splenic plasma cell numbers, along with serum titers, were reduced in the recall 




secondary response are B cell intrinsic, as demonstrated by mixed bone marrow 
chimera studies182. Future studies involving immunohistochemistry staining of 
splenic sections will be required to determine the precise splenic localization of 
T-bethigh B cells relative to their T-betlow and T-bet- counterparts. It will also be 
important to determine differences in chemokine and cytokine receptor profiles 
between these subsets and to determine how these contribute to localization and 
recirculation properties. Assuming that splenic resident T-bethigh B cells are 
preferentially localized to the splenic MZ, it is tempting to postulate that they are 
poised to rapidly differentiate into antibody secreting cells and produce 




CHAPTER 5: Materials and Methods 
Mice: C57BL/6 and B6.SJL (10-12 weeks old, females, purchased from The 
Jackson Laboratory); Tbx21F/F possessing loxP sites flanking exons 2-6 of 
Tbx21183 and Cd19tm1(cre)Cgn containing a targeted cre cassette into exon 2 of 
Cd19184 (obtained from the laboratory of E. John Wherry, University of 
Pennsylvania); Tbx21-ZsGreen with a ZsGreen reporter gene inserted at the 
Tbx21 start site in BAC RP23-237M1486; Tbx21-ZsGreencreERT2 possessing the 
BAC RP23-237M14 with the ZsGreen reporter gene, T2A self-cleaving peptide, 
and inducible creERT2 recombinase gene123; and Rosa26LSL/tdTomato with a 
Rosa26 targeted construct containing CAG-LSL-tdTomato-WPRE135 were 
maintained and used in accordance with the University of Pennsylvania 
Institutional Animal Care and Use Committee guidelines.  
 
Infections: Mice were infected by intranasal infection with 30 tissue culture 
infectious dose50 (TCID50) of influenza strain A/Puerto Rico/8/1934 (PR8; 
American Type Culture Collection).  
 
Parabiosis and separation surgery: Age-matched T-bet ZsGreen reporters and 
B6.SJL adult female mice were conjoined as described previously185. Briefly, a 
skin incision was made from the olecranon to the knee of each of the mice to be 
joined. The elbows and knees of the two paired mice were then tied together with 
surgical suture, followed by connecting of the skin with surgical sutures and 




hours for 36 hours) and meloxicam (5 mg/kg every 12 hours for 72 hours) and 
provided with sulfamexathole (400mg/L) and trimethoprim (800mg/L) antibiotics 
in their drinking water to prevent infection. Mice were monitored for signs of pain, 
infection, or damage to sutures. Blood was periodically drawn from the tail to 
check for anastomoses, which appeared complete by day 14, therefore, mice 
were euthanized at day 17. The spleen was harvested from both partners for all 
pairs, and the lungs and mediastinal LNs were also collected from some pairs. 
Seperation surgery was performed similar to parabiosis surgery except an 
incision was made from the olecranon to the knee of the paired mice and the 
joining suture was severed after which sutures were used to appose the dorsal 
and ventral skin flaps in each partner. Mice were maintained for a minimum of 
three weeks following separation surgery. 
 
Flow cytometry: Flow cytometry reagents were purchased from BioLegend 
(BL), BD Biosciences (BD), eBioscience (eBio), Southern Biotech (SB), or 
Invitrogen (Inv). The following antibodies were used: CD11c (N418; BL), IgM 
(R6-60.2; BD), CD38 (90; eBio), CD73 (TY/11.8; BL), CD80 (16-10A1; BD or BL), 
PD-L2 (TY25; BL), CD138 (281-2; BL), IgD (11–26c.2a; BL), B220 (RA3-6B2; BL 
or eBio), CD19 (1D3; BD or eBio), CD19 (6D5; BL) peanut agglutinin–FITC 
(Sigma), CD45.1 (A20; BL), CD45.2 (104; BL), CD183/CXCR3 (CXCR3-173; BL) 
and CD3 (17A2; BL). DUMP gate comprised CD8 (53-6.7; eBio), CD4 (H129.19; 
BL), F4/80 (BM8; eBio), Ly-6G/GR1 (RB6-8C5; eBio). For detection of murine 




from the laboratory of Dr. Barney Graham, National Institute of Allergy and 
Infectious Disease, biotinylated, and conjugated to streptavidin-fluorophores as 
previously described186. Mouse samples were prepared for flow cytometry as 
follows: Mouse Fc fragment (Jackson ImmunoResearch; 015-000-008) was 
added to all staining cocktails at a final concentration of 1:200. Mouse spleens 
were homogenized, on ice, in staining buffer (PBS + 0.5%BSA + 2mM EDTA) 
and passed through nylon mesh (50μM) to obtain single cell suspension. Bone 
marrow was flushed from the femur and tibia with staining buffer following 
removal of muscles and and passed through nylon mesh (50μM). Red blood cells 
were lysed using ACK lysing buffer (Lonza, cat 10-548E) as per manufacturer’s 
instructions. Mouse LNs were homogenized, on ice, in staining buffer and passed 
through nylon mesh (50μM). Cells were washed with PBS and stained as 
described previously41, 60. Live/dead discrimination was done using Zombie Aqua 
fixable viability kit (BL). Data were acquired on BD LSR II flow cytometer and 
FACS analyses were performed using FlowJo v9 and v10 (Becton Dickinson Co., 
Ashland, OR). 
 
Serum antibody titers: Serum was harvested by spinning whole blood at 
13000g for 10 minutes and stored at -20°C until use. Antibody titers were 
assessed using ELISA as previously described41, 60 with the following 
modifications: 96-well medium-binding plates were coated with either 20HAU/well 
of BPL-inactivated PR8, 2 μg/mL of PR8 HA, or 2 μg/mL of H6/H1 chimeric 




specific monoclonal antibodies (from Dr. Jonathan Yewdell, National Institute of 
Allergy and Infectious Diseases) were used as standards to determine 
concentration of IgG1 and IgG2a/c. Standards were used at a starting 
concentration of 100 ng/mL for IgG2a and 10 ng/mL for IgG1 and diluted 2-fold 
across.  
 
HAU (hemagglutination unit) and HAI assays: Viral HAU titers were 
determined before every HAI assay. All dilutions were prepared in PBS. 50 μL 
diluted virus, 50 μL diluted heat-inactivated sera and 12.5 μL of 2% turkey 
erythrocytes were used per well for all assays, which were performed in round-
bottom plates.  
Starting with a 1:100 dilution of live virus, 2-fold dilutions were mixed with 
2% turkey erythrocytes (Lampire biologicals) and incubated for 1 hour at room 
temperature. Agglutination dose (AD) was determined at the end of the 
incubation period, and confirmed by repeating the process with a 2-fold dilution 
series of virus, ranging from 4AD to 0.25 AD. This dose was subsequently used 
for the HAI assay. 
Sera were heat-treated at 55°C for 30 minutes, diluted 2-fold in PBS 
(staring dilution 1:20), mixed with 4AD and 2% turkey erythrocytes, and 
incubated as for HAU assay. HAI titers are expressed as inverse of the highest 





Tamoxifen Treatment: Tamoxifen (Sigma; cat. T5648-1G) was dissolved in 
100% ethanol to a concentration of 80 mg/ml and vortexed and heated at 42°C 
until completely dissolved. An equal volume of Kolliphor (Sigma, cat. C5135-
500G) was added to bring the solution to a concentration of 40 mg/ml. Aliquots 
were then stored at -20°C. Immediately prior to administration, tamoxifen aliquots 
were thawed at 42°C and diluted with PBS to 8 mg/ml. Mice were administered 
three doses of 0.8 mg of tamoxifen via intraperitoneal injection every other day.  
 
Cell Sorting: Murine splenocytes were prepared as described prior then 
negatively selected using a cocktail of biotinylated antibodies against CD4 (RM4-
5, eBio), CD8a (53-6.7; eBio), F4/80 (BM8; eBio), Ly-6G/GR1 (RB6-8C5; BD), 
and Ter-119 (Ter-119; BL). After washing with staining buffer, cells were 
incubated with 100ul Streptavidin MicroBeads (Miltenyi Biotec) in 900ul staining 
buffer for 30 min. Cells were then washed and ran through a negative selection 
LD column (Miltenyi Biotec) according to manufacturer’s instructions. Flow thru 
was collected and washed with staining buffer then stained for FACS. Samples 
were sorted on a BD FACS Aria into serum supplemented media and stored on 
ice. Sorted samples were centrifuged and resuspended in 100-200ul PBS for 
retroorbital injection into recipient B6.SJL mice.  
 
BrdU Administration and Staining: Mice were injected IP with 200 ul of 3 




given drinking water with 1mg/ml sucrose and 0.5 mg/ml BrdU until takedown. 
Splenocytes were harvested and stained as described prior then prepared for 
intracellular staining with the Fix and Perm Cell Fixation and Permeabilization Kit 
(ThermoFisher) according to manufacturer’s instructions. After ICS, cells were 
treated with DNAse solution for 40 minutes, washed, and stained with anti-BrdU 
APC antibody (BD) for 40 minutes at 1:80 dilution in FACS buffer. Cells were 
washed and stored at 4 degrees in the dark until running on the cytometer.  
 
QUANTIFICATION AND STATISTICAL ANALYSIS:  
All p values were determined using one of the following as mentioned in figure 
legends: unpaired non-parametric t-test or paired t-test using GraphPad Prism 
version 7 or version 8 (GraphPad Software, La Jolla, CA 92037 USA). ns=not 
significant, *p < 0.05, **p < 0.01, ****p < 0.001. Data are represented as mean ± 
SEM or mean± SD. The number of mice used in each experiment, as well as the 





REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies (clone)                              Company                           Catalog number 
CD11c (N418) Biolegend 117318 or 117333 
IgM (R6-60.2) BD Biosciences 562565 
CD38 (90) eBioscience 56-0381-82 
CD73 (TY/11.8) Biolegend 127231, 127215 or 127230 
GL7 (GL7) Biolegend 144619 
CD80 (16-10A1) Biolegend; BD Biosciences 104731 or 104708; 563687 
PD-L2/CD273 (TY25) Biolegend 107206 
Streptavidin BV421 Biolegend 405226 
Streptavidin AF647 Invitrogen S32357 
CD138 (281-2) Biolegend; BD Biosciences 142516; 553713 
IgD (11–26c.2a) Biolegend 405725 or 405731 
B220 (RA3-6B2) Biolegend; eBioscience 103207, 103226 or 103246; 
47-0452-82 
CD19 (1D3) eBioscience; BD 
Biosciences 
35-0193-82; 557655 or 
550992 
CD19 (6D5) Biolegend 115543 
peanut agglutinin–FITC Sigma-Aldrich L7381-1MG 
CD95 (SA367H8) Biolegend 152612 
CD45.1 (A20) Biolegend 110743 




CD3 (17A2) Biolegend 100209 
CD8a (53-6.7) BD Biosciences; 
eBioscience 
553034; 13-0081-85 
CD4 (H129.19) Biolegend 130312 
CD4 (RM4-5) eBioscience 13-0042-85 
F4/80 (BM8) Invitrogen; eBioscience 15-4801-82; 15-4801-82 
Ly-6G/GR1 (RB6-8C5) Biolegend; BD Biosciences 108410; 553125 
Ter-119 (Ter-119) Biolegend 116204 
Zombie Aqua fixable viability 
kit 
Biolegend 423102 
Mouse Fc fragment Jackson Immunoresearch 015-000-008 
   
Bacterial and Virus Strains    
Influenza strain A/Puerto 
Rico/8/1934 (PR8) 
American Type Culture 
Collection 
 
   
Biological Samples   
Turkey Erythrocytes Lampire Biologicals Cat# 7209401 
   








Laboratory of Dr. Barney 
Graham, National Institute 
of Allergy and Infectious 
Disease 
Whittle et al., 2014 
HA-specific monoclonal 
antibodies (IgG1 and 
IgG2a/c) 
Laboratory of Dr. Jonathan 
Yewdell, National Institute of 
Allergy and Infectious 
Diseases 
 
H6/H1 chimeric constructs Laboratory of Scott E. 
Hensley, University of 
Pennsylvania 
Margine et al., 2013 
Meloxicam Boehringer Ingelheim NDC 0010-6013-
01 




Aurobindo NDC 65862-496-47 
Isoflurane Phoenix 0010250 
Tamoxifen Sigma-Aldrich T5648 
Kolliphor Sigma-Aldrich C5135 
   
Critical Commercial Assays   
Streptavidin MicroBeads Miltenyi Biotec 130-048-101 
LD Columns Miltenyi Biotec 130-042-901 
Fix and Perm Cell Fixation 
and Permeabilization Kit 
ThermoFisher GAS003 
APC BrdU Flow Kit BD Biosciences 552598 




Mouse: C57BL/6  The Jackson Laboratory MGI:5656552 
Mouse: B6.SJL The Jackson Laboratory Jax Stock No: 002014 
Mouse: Tbx21flox/flox from the laboratory of E. 
John Wherry, University of 
Pennsylvania 
Jax Stock No: 022741 
Mouse: Cd19cre/+ from the laboratory of E. 




Mouse: Tbx21-ZsGreen from the laboratory of 
Jinfang Zhu, National 
Institutes of Health 






from the laboratory of 
Jinfang Zhu, National 
Institutes of Health 
Yu et al., 2015; 
MGI:5690125; MGI:3809524 
   
Software and Algorithms   
FlowJo v9 and v10 Becton Dickinson Co., 
Ashland, OR 
Prism V7 and V8 GraphPad, La Jolla, CA 
Table	1:	List	of	Key	Resources 
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